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Abstract 
 
Tendon connects skeletal muscle to bone and transmits force generated from 
muscular contraction to produce locomotion. Despite the importance of tendon to the 
overall function of the musculoskeletal system, relatively little is known about the cellular 
and molecular mechanisms that control its growth, maintenance and repair. This lack of 
knowledge represents a significant barrier to improved management of tendon injuries, 
which remains difficult with poor outcomes. The objective of this dissertation was to 
determine the role of key signaling pathways activated during tendon growth and injury, 
and to investigate the biological mechanisms behind these responses. Since a central 
feature of tendon disorders is abnormal fibroblast morphology and a grossly disrupted 
appearance of the tendon extracellular matrix (ECM), my overall working hypothesis is 
molecular programs that regulate the interaction between tendon fibroblasts and their 
local ECM environment during tendon growth play an important role in the healing 
response of injured tendons. Herein, initial studies identified epithelial-to-mesenchymal 
transition and matrix metalloproteinases as important sets of genes upregulated in the 
proliferative and remodeling phases of tendon regeneration. A large number of these 
genes are known to be regulated by a family of receptor tyrosine kinases known as the 
platelet-derived growth factor receptors (PDGFRs), yet the role of PDGFR signaling in 
tendon growth and remodeling has remained largely unexplored. Using hindlimb 
	 xi 
synergist ablation to overload tendons and induce tendon growth in mice, we showed 
that tendon fibroblasts express both PDGFRs, PDGFRα and PDGFRβ, and the 
inhibition of PDGFR signaling suppressed the normal growth of tendon tissue after 
mechanical overload due to defects in fibroblast proliferation and migration. Membrane 
type-1 matrix metalloproteinase (MT1-MMP) was also identified as an essential 
proteinase for fibroblast migration through tendon ECM. Using a combination of small 
molecule inhibitors and cell-surface biotinylation experiments, we showed that MT1-
MMP translation was regulated by PI3K/Akt within tendon fibroblasts, while ERK1/2 
controlled post-translational trafficking of MT1-MMP. Taken together, these findings 
demonstrate that PDGFR signaling is necessary for postnatal tendon growth and 
remodeling, and that MT1-MMP is a critical mediator of tendon fibroblast migration and 
a potential target for the treatment of tendon injuries and diseases.  
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Chapter I 
 
Introduction 
 
Background 
The musculoskeletal system provides structural support, maintains form and 
permits movement of the body. Comprised of skeletal muscle, tendon and bone, each of 
these tissues display a remarkable ability in their adaptation to various physiological and 
pathological stimuli, which is important in determining the overall health and functional 
capacity of an individual. While a great deal is known about the growth processes of 
skeletal muscle and bone, the specific factors controlling the growth and remodeling of 
tendon tissue have not been clearly defined. Additionally, whereas treatment options for 
tendon injuries and diseases are quite limited, many therapeutic agents are currently in 
development for disorders of skeletal muscle and bone, and these therapies are derived 
from knowledge of the cellular and molecular mechanisms controlling growth of these 
tissues. In adult skeletal muscle, satellite cells are resident stem cells that play a critical 
role in muscle regeneration, and many therapies being tested for muscular dystrophies 
and sarcopenias target these cells (21, 67). In bone, the study of osteoclast-directed 
bone resorption has led to the development of bisphosphonates for the treatment of 
osteoporosis (11). In this regard, studies investigating the fundamental biology of 
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tendon growth and remodeling hold great potential for making a substantial impact on 
the management of tendon injuries and diseases. 
Tendons are anatomically situated between force-generating muscles and the 
rigid support of the skeleton. Given this unique position between contractile and non-
contractile tissues, tendons have the dual responsibility of transmitting force generated 
by muscular contractions to produce locomotion, while at the same time protecting the 
muscle from injury by limiting the strain placed on the muscle fibers (10). Since tendon 
is more compliant than bone, differences in strain concentration between these 
mechanically different tissues results in increased susceptibility of the tendon tissue to 
injury (51). Tendinopathy, a chronic degenerative process causing pain in and around 
tendon tissue, is a common clinical problem that accounts for 7% of all patient 
encounters seen in the United States on a yearly basis (68). Tendinopathies also 
account for 30-50% of all injuries in sports and the risk of these injuries are increasing 
as a larger proportion of young and old age groups participate in recreational activities 
(1). Additionally, organized sports programs have placed greater demands on athletic 
performance, requiring that athletes train longer, harder and more often, and chronic 
overuse has been shown to increase the risk of developing tendinopathy (65). 
Interestingly, while an increased level of physical activity is a strong predictor of 
sustaining a tendon injury, a large proportion of cases are observed in those who lead a 
sedentary lifestyle (41, 43, 53, 68). The quality of life for patients with tendinopathy is 
significantly impaired due to constant pain and loss of function. The mainstays of 
treatment have been to reduce inflammation and maintain mobility through physical 
therapy, but many patients have poor outcomes and continue to experience pain 
	 3 
despite treatment (68, 77). Thus, a more direct approach to the management of 
tendinopathies is greatly needed, and the current lack of targeted therapies is due in 
part to our limited mechanistic insight into the basic physiological processes controlling 
the growth and remodeling of tendon tissue. 
The objective of this dissertation was to determine the role of key signaling 
pathways activated during tendon growth and injury, and to investigate the biological 
mechanisms behind these responses. Since a central feature of tendon disorders is 
abnormal fibroblast morphology and a grossly disrupted appearance of the tendon 
extracellular matrix (ECM), my overall working hypothesis is molecular programs that 
regulate the interaction between tendon fibroblasts and their local ECM environment 
during tendon growth play an important role in the healing response of injured tendons. 
In this introductory chapter, the normal structure and function of tendon are first 
discussed, along with a concise review of tendon mechanics. Signaling by receptor 
tyrosine kinases (RTKs) is then summarized, as these signaling pathways emerged 
from this work as critical to the regulation of tendon growth. This chapter concludes with 
a brief synopsis of tendinopathies and the potential to improve their management 
through basic science research. 
 
Tendon Structure and Function 
Tendons connect skeletal muscle to bone and transmit force generated by 
muscular contraction to permit movement. They are considered an extension of the 
skeletal muscle ECM and terminate on bone at the enthesis (10). Tendons vary in size 
and shape with short, thick tendons originating from the powerful muscle groups of the 
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proximal limb, while long, thin tendons execute fine movements of the digits (29). 
Smooth and efficient motion requires tendon gliding that is not restricted by adjacent 
tissue. For this reason, synovial sheaths form a closed system around many tendons to 
provide lubrication and cushion the tendon as it stretches and relaxes (10). Tendons 
that lack true synovial sheaths are instead surrounded by a loose, fatty and 
vascularized peritendinous tissue, which allows for free excursion of the tendon within 
its fascial compartment (29). 
Tendon is a hypocellular tissue composed of elongated fibroblasts interspersed 
between a complex network of matrix proteins. The organizational pattern of tendon 
closely resembles that of skeletal muscle with distinct connective tissue layers running 
parallel to its longitudinal axis (29). The smallest functional unit of tendon is the collagen 
fibril. Collagen fibrils combine to form larger collagen fibers, and then groups of these 
fibers coalesce into tendon fascicles. The process of collagen fibril formation is 
described in more detail later. Tendon fascicles are enveloped by the endotenon, which 
is a delicate reticular network of connective tissue supporting a rich supply of vascular, 
lymphatic and neural channels (29). The tendon proper is the final structure formed by 
numerous tendon fascicles held together by a loose epithelial-like tissue layer called the 
epitenon (72). The epitenon contains larger blood vessels and nerves, and is a potential 
source of new tendon fibroblasts during periods of tendon growth and repair (19, 46). 
During the course of embryonic development, tendons arise from a separate pool 
of progenitor cells than other limb tissues, including skeletal muscle, cartilage and bone 
(61). Tendon fibroblasts are rod- or spindle-shaped cells with long cytoplasmic 
extensions whose primary function is to synthesize and secrete collagen and other 
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matrix proteins (6). The density of fibroblasts in tendon is highest at birth and then 
steadily declines throughout the lifespan of an individual (42). Along similar lines, 
Ippolito and colleagues (26) originally described two different populations of tendon 
fibroblasts, namely immature proliferating tenoblasts and terminally differentiated 
tenocytes. As individuals approach adulthood, the number of tenoblasts decrease while 
terminally differentiated tenocytes become the most abundant cell population in tendon 
(19). The origin and identity of the stem cell population within tendon that gives rise to 
tenocytes is not fully understood. However, pericytes, which are a population of stem 
cells that exist in close proximity to the vasculature, appear to be attractive candidates 
(60). The remaining cells within tendon mostly consist of endothelial and smooth muscle 
cells of the tendon vasculature, synovial cells within the tendon sheath and 
chondrocytes at the enthesis (65). 
The main structural protein of tendon is type I collagen, which accounts for 65-
80% of the tendon dry weight (34). Type I collagen is first synthesized as a procollagen 
molecule within the tendon fibroblast and typically consists of two α1 and one α2 
subunits. Procollagen is then secreted from the cell into the tendon ECM where its 
amino- and carboxy-terminal ends are cleaved to produce tropocollagen. As the final 
step in the collagen synthesis pathway, multiple tropocollagen molecules are covalently 
cross-linked resulting in the formation of the mature collagen fibril. Type I and III 
collagen are part of the fibrillar collagen family and play an important role in the 
longitudinal transmission of force during locomotion (10). Compared to type I collagen, 
type III collagen tends to be smaller in diameter, less organized and has decreased 
tensile strength (4). Type III collagen is often found at increased levels in aged tendon 
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or at the rupture sites of highly stressed tendons (13). Type V collagen is also a fibrillar 
collagen, but is present in lesser quantities and regulates the initiation of collagen fibril 
assembly (79). In addition to the fibrillar collagens, many other types of collagen can be 
found in tendon. These collagens, such as the network type IV and VI collagens, help to 
transmit forces laterally between cells and provide structural support for vascular and 
lymphatic tissue in the endotenon and epitenon (10). Mice deficient in type VI collagen 
display mechanically weak tendons with an increase in the number of small and 
aberrant collagen fibrils, indicating that type VI collagen also facilitates collagen fibril 
organization (27). Aside from collagen, a small but significant portion of the tendon 
structure in humans is formed by elastin (29). While little is known about its exact 
function, elastin tends to be localized to the interfascicular matrix and likely contributes 
to sliding between adjacent tendon fascicles and recoil after mechanical loading (63). 
Finally, intermixed with the collagen and non-collagen proteins of the tendon ECM is the 
gelatinous ground substance composed of proteoglycans (PGs) and 
glycosaminoglycans (GAGs). PGs and GAGs have a fixed net negative charge that 
allows them to retain water, which in turn helps the tendon to dissipate heat into the 
surrounding tissues as well as resist high compressive and tensile forces during 
exercise (81). 
In humans, the core of the Achilles tendon will grow until the age of 17, after 
which protein synthesis and matrix turnover begin to decline (22). This is supported by 
animal studies in rodents that demonstrate tendon growth mostly occurs in an outward 
direction from the epitenon (19, 60). However, the lack of a discernible endotenon in 
rodents makes it difficult to rule out the possibility of intrafascicular growth between 
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tendon fascicles. Taken together, these findings suggest that the lack of tissue renewal 
in the core of adult tendon tissue may explain why many patients fail to improve with 
conservative management, and perhaps cell-based therapies that selectively utilize a 
fraction of cells from those connective tissue layers known to be enriched in tendon 
stem cells may enhance the regeneration of injured tendon tissue. 
The most commonly used methods to study tendon growth in mice include 
treadmill running and hindlimb synergist ablation. Treadmill running is the most 
physiologically relevant model, and involves mice running on a treadmill for defined 
periods of time with progressive increases in speed, distance and incline (46). The main 
disadvantage of this technique is that most protocols require at least four weeks of 
running before any measurable changes can be observed. Additionally, motivating mice 
to run can be a difficult task, even when enclosed treadmills with shock grids are used 
(35), and constant vigilance is required from the investigator to ensure all the mice run 
equally for the entire duration of the protocol (17). While the hindlimb synergist ablation 
model is routinely used to study skeletal muscle growth (5, 45, 47), it also causes rapid 
and robust growth of the plantaris tendon (19). The procedure involves surgical excision 
of the midsubstance of the Achilles tendon to prevent the gastrocnemius and soleus 
muscles from plantarflexing the talocrural joint, resulting in compensatory hypertrophy of 
the synergist plantaris musculotendinous unit. Despite the early and reproducible results 
of this model, the disadvantages include the use of a supraphysiological load to induce 
tendon growth and the need for the investigator to have proficiency in small animal 
surgery. 
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Tendon Mechanics 
The mechanical properties of tendon are determined by the macromolecular 
structural organization and biochemical composition of the tendon ECM (34). In general, 
positive adaptations of tendons to mechanical growth stimuli include increases in 
tendon cross-sectional area (CSA), cell density, peak stress, peak strain and type I 
collagen synthesis (19, 32-34, 44, 46, 80). At rest or during unloading, collagen fibrils 
exhibit a characteristic wavy or crimped pattern. This is the result of lateral and 
longitudinal stacking of tropocollagen molecules that takes place during collagen fibril 
assembly (78). When uniaxial tension is applied to the tendon, the stress-strain curve 
displays a nonlinear relationship and consists of three distinct regions (Figure 1.1). 
Stress is calculated as force normalized to the tendon CSA, while strain is measured as 
displacement normalized to the tendon resting length (44, 78). In the initial toe region of 
the stress-strain curve, which represents strains up to 2%, the slope is nonlinear and 
the crimp pattern disappears as the collagen fibrils straighten (65). Beyond this point, 
collagen fibrils orient themselves in the direction of the tensile force, and the tendon 
deforms in a linear manner due to intramolecular sliding between tropocollagen 
molecules (65). Strains less than 4% generally allow the tendon to return to its original 
length once the load is removed, but above 4% strain the collagen fibrils begin to fail 
(29, 65). The slope of the stress-strain curve in this linear region represents the Young’s 
modulus, which measures the resistance of the tendon to deformation while under load, 
and provides useful information on the intrinsic mechanical properties of tendon (44). 
Finally, in the yield or failure region of the stress-strain curve, the tendon reaches its 
physiological limit at about 8-10% strain, which results in irreversible deformation and 
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visible rupture due to breakage of the intermolecular cross-links between collagen fibrils 
(29, 65). 
Tendon is considered a viscoelastic tissue, and as such, it displays 
characteristics of both elastic solids and viscous fluids in response to loading and 
unloading. When a tendon is loaded, the extent of tissue deformation is dependent on 
the rate at which the load is applied (51). At low strain rates, tendons deform more and 
absorb more energy, while at high strain rates, tendons deform less, become stiffer and 
are more effective at carrying mechanical loads (78). The ground substance, which 
attracts and retains water due to the strong polyanionic charge of the PGs and GAGs, is 
one of the chief contributors to the viscoelasticity of tendon (51, 81). As tendons are 
stretched, the interstitial fluid is squeezed out of the tendon ECM and hydrogen bonds 
between the amino acid residues of collagen and water molecules are broken, which 
gives off energy in the form of heat (12, 51). Hysteresis refers to this loss of energy 
during tendon deformation, and as a result, the stress-strain curves for loading and 
unloading appear different (51). In situations of high-frequency cyclical stretching, 
certain regions of the tendon may not be able to efficiently dissipate heat into the 
surrounding tissues, which may cause irreversible denaturing of matrix proteins, and 
possibly lead to tendinopathy or acute tendon rupture (57). Lastly, two additional 
features that highlight the viscoelastic properties of tendon are creep and stress 
relaxation. Creep refers to time-dependent elongation of the tendon while under 
constant load, whereas stress relaxation is a time-dependent decline in the load 
required to maintain constant elongation of the tendon (44). 
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An additional factor that strongly influences the mechanical properties of tendon 
is the degree to which tropocollagen molecules are covalently cross-linked. As tendons 
are stretched, heat is generated from friction as the tropocollagen molecules slide past 
each other (51). One potential mechanism to reduce this fibrillar sliding, and hence the 
production of heat, is to increase the density of cross-links between tropocollagen 
molecules (51). Greater collagen cross-linking will also result in secondary changes 
within the tendon tissue, such as increased stiffness and a decreased amount of energy 
lost during loading and unloading (52). The formation of cross-links between 
tropocollagen molecules is a complex post-translational modification that can occur by 
two different methods, namely enzymatic cross-linking or non-enzymatic glycation (56). 
Enzymatic cross-links are mediated by lysyl oxidase, which produces highly reactive 
aldehyde groups on the lysine and hydroxylysine residues of tropocollagen molecules 
that then react with similar residues to form stable covalent bonds (54), whereas non-
enzymatic cross-links are formed when lysine and hydroxylysine residues come into 
contact with a reducing sugar (55). The accumulation of non-enzymatic cross-links 
derived from the addition of glucose adducts is a signature finding in aged and diabetic 
tendons (55). These advanced glycation end products (AGEs) can alter the mechanical 
properties of tendon and lead to progressive degeneration of the tendon ECM, which 
increases the risk of developing tendinopathy (66). Finally, independent of the effect 
that AGEs have on tendon, aging in itself causes a gradual decline in the structure and 
function of tendon. Compared to young tendons, aged tendons typically demonstrate 
increased stiffness, a decreased rate of type I collagen synthesis and a decreased 
	 11 
content of elastin and PGs, which all contribute to an increased risk for spontaneous 
rupture of the tendon (28, 75). 
 
Pathogenesis and Management of Tendinopathies 
Tendinopathy is a frequent and difficult to treat clinical problem that invariably 
leads to a negative impact on the functional capacity of an individual. It is often 
considered a failure of damaged matrix proteins within the tendon to properly heal, but 
the exact etiology remains largely unknown. Hallmark findings of this disorder include 
localized pain, swelling and reduced strength and performance of the affected tendon. 
While frequently thought to be associated with increasing age and participation in 
sports, tendinopathy is routinely diagnosed in patients of all ages and levels of physical 
activity (1). Management of this painful condition can be particularly challenging and 
recovery is usually slow (65). This is especially true for athletes where higher levels of 
physical activity and minimal rest times make it difficult to return to sports and can lead 
to re-injury. Numerous treatment options exist for tendinopathy, but overall there is a 
lack of consensus in the literature regarding their efficacy. Indeed, some tendinopathies 
respond to simple interventions, while others are refractory to nearly all forms of 
treatment. Our insight into the pathophysiology of these diseases is constantly evolving 
and more sophisticated treatment strategies continue to emerge as new information is 
acquired through rigorous scientific pursuit. 
Understanding the pathogenesis of tendinopathy has been hindered by a lack of 
consistent terminology. Traditionally, the term tendinitis referred to symptomatic tendons 
associated with chronic pain and implied an element of inflammation in its basic 
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etiology, especially in the initial phases of the disease process (48). Repetitive 
microtrauma from overload or overuse can lead to collagen fibril rupture and activation 
of the innate immune system (48). However, continued research has demonstrated little 
to no biochemical or histological evidence of inflammation in biopsies from patients with 
chronic tendinopathy (2). Given the uncertainty surrounding the role of inflammation in 
the development of tendon disorders, we prefer to use the term tendinopathy to 
describe an ongoing process of degeneration and failed regeneration of the tendon 
ECM in response to injury or disease. In clinical practice, tendinopathy refers to a 
spectrum of pathologies from intratendinous degenerative lesions that are a source of 
chronic pain, to spontaneous tendon rupture as a result of mechanical attrition. 
Several features are characteristic of tendinopathy at the microscopic level 
(Figure 1.2). Compared to healthy tendons, tendinopathic tendons have marked 
disorganization and separation of collagen fibrils with a concomitant increase in mucoid 
ground substance (31). Collagen fibril diameter is more variable and an increased 
content of type III collagen contributes to mechanical weakness of the diseased tendon 
(13). Tendon fibroblasts adopt a rounded rather than flattened appearance and tend to 
be unevenly distributed throughout the tissue. Another hallmark feature of tendinopathy 
is neovascularization with budding capillaries invading the tendon from the paratenon 
(31). These capillaries are usually accompanied by the ingrowth of sensory nerve fibers 
that release nociceptive substances and trigger pain (59). Finally, there is absence of an 
inflammatory cell infiltrate in the tendon proper, although inflammation can be observed 
within the peritendinous tissue (31). 
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The management of tendinopathy can vary based on the history and extent of 
the condition, the severity of symptoms, and the physical demands and activity level of 
the patient. At the moment, conservative measures remain the mainstay of treatment for 
most tendinopathies. Rehabilitation, with a focus on eccentric exercises, should be a 
first-line therapy along with nonsteroidal anti-inflammatory drugs (NSAIDs) for short-
term symptomatic relief (1). However, prolonged use of NSAIDs should be avoided due 
to the risk of complications and lack of proven long-term benefit. Second-line therapies 
include prolotherapy, platelet-rich plasma (PRP) injections and topical nitric oxide 
patches. As a group, the data for these are inconclusive, but their risks are low and 
therefore can be recommended for patients that fail first-line treatment (68). 
Corticosteroids should be used with caution in the treatment of tendinopathies, as the 
underlying cause likely does not involve inflammatory changes and their use may 
increase the risk of spontaneous tendon rupture (1). Nearly a third of all patients with 
tendinopathy fail nonoperative management (1). Surgery should only be pursued for 
recalcitrant cases when conservative measures have failed, or for patients with obvious 
operative lesions. The goal of operative management for patients with tendinopathy is to 
either remove the pathological areas of tendon or to induce low grade trauma to the 
chronically degenerated tendon ECM in an effort to restart the healing process. 
A major limitation of basic science research in studying human tendinopathies is 
the lack of representative animal models. To date, not a single animal model exists that 
can fully recapitulate the biochemical and histological findings observed in diseased 
tendon tissue isolated from humans. The two most common techniques used to induce 
a tendinopathic-like condition in animals are collagenase injection and downhill treadmill 
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running. Collagenase injection causes proteolytic destruction of the tendon ECM (7-9, 
37), but the main problem with this approach is that the collagenase enzyme is derived 
from the bacterium Clostridium histolyticum. Recognized as a foreign material by the 
body, the enzyme causes a local inflammatory reaction in addition to proteolysis that is 
uncharacteristic of tendinopathies. In contrast to the collagenase model of tendinopathy, 
downhill treadmill running invokes tendinopathy through a change in the mechanical 
environment rather than through use of a chemical agent. Developed by Soslowsky and 
colleagues (69), rats are subjected to a running protocol that equates to a total daily 
distance of 1 km and occurs at a 10° decline. While this model causes less inflammation 
than the collagenase injection, the damage that occurs to the supraspinatus tendon 
likely results from impingement of the tendon on the acromion rather than a true 
tendinopathy that develops from chronic overuse. Finally, there are presently no 
transgenic models of human tendinopathy, owing to the lack of cellular and molecular 
targets for gene inactivation. Improved animal models of human tendinopathy are 
greatly needed to help elucidate the basic mechanisms that underlie chronic 
degeneration of the tendon ECM, and to facilitate the development of better prevention 
and treatment strategies for this complex disease process. 
 
Receptor Tyrosine Kinase Signaling 
RTKs are an evolutionarily conserved family of high-affinity cell surface receptors 
that upon growth factor binding activate a complex network of intracellular signaling 
pathways. In humans, there are 58 known RTKs, which can be grouped into 20 
subfamilies based upon the sequence homology of their cognate ligands (40). While 
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there are slight differences in the structural mechanisms by which ligands induce RTK 
oligomerization and activation, most of this review will focus its discussion of RTK 
signaling on the platelet-derived growth factor receptors α (PDGFRα) and β (PDGFRβ), 
since these receptors are targeted in Chapter III. PDGFRs play an important role in 
many developmental programs, primarily within mesenchymal tissues, due to their 
ability to regulate a diverse set of cellular responses, including proliferation, 
differentiation, cell survival, metabolism, cell migration and cell-cycle control (40, 76). 
Additionally, dysfunctional PDGFR activity has been implicated in a myriad of diseases 
such as cancer, diabetes, inflammation and atherosclerosis (3, 40). Although PDGFRs 
are essential components of complex signaling networks that are active during 
embryonic development and in numerous pathological conditions, there is limited 
evidence to support the role of PDGFR signaling in normal physiological functions, such 
as tissue growth, in the adult (3). 
In general, all RTKs share a similar structure that consists of an extracellular 
ligand-binding domain at the N terminus, a single-pass hydrophobic transmembrane 
domain and an intracellular conserved tyrosine kinase domain (TKD) at the C terminus 
(40, 76). The extracellular region tends to be of variable length and composition, while 
the intracellular region is the most conserved, and sometimes contains a TKD that is 
separated into two parts by a short sequence known as the kinase insert domain (KID), 
which is typical of the PDGFRs (40). The PDGFRs are present at the cell membrane as 
monomers, and have an extracellular region that consists of five immunoglobulin-like 
repeats (3, 58). In the absence of ligand binding, the catalytic site of the kinase is 
sterically blocked by an activation loop, which is an important regulatory element found 
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in the TKD of the PDGFRs (50). This state of suppressed PDGFR kinase activity is 
referred to as cis-autoinhibition, and is further stabilized by sequences within the 
juxtamembrane region that come into contact with the activation loop (40). Upon ligand 
binding and receptor dimerization, key tyrosine residues in the juxtamembrane region 
and activation loop are autophosphorylated in trans, which destabilizes the 
autoinhibitory interactions and induces a conformational change that promotes PDGFR 
activation (25, 40). Signaling and adaptor proteins can then recognize these and other 
phosphotyrosine residues, and bind to them in a sequence-specific manner through the 
use of Src homology 2 (SH2) and phosphotyrosine-binding (PTB) domains for signal 
propagation (3). 
Both PDGFRα and PDGFRβ activate multiple downstream signaling pathways 
that control key biological functions in many different cell types. The expression patterns 
of the PDGFRs can be complex, but PDGFRα is mainly expressed by mesenchymal 
cells and PDGFRβ has particularly strong expression in the vasculature and by 
perivascular cells (3). While PDGFR phosphorylation is known to recruit at least 10 SH2 
domain-containing proteins, a dominant signaling pathway has yet to be identified for 
either receptor subtype (23, 24). However, the prevailing concept at the moment is that 
PDGFRs activate redundant signaling pathways that control transcription of a common 
set of genes such that the role of any individual signaling pathway is less important than 
their additive effect on the transmitted signal (14, 39). Nonetheless, the major signaling 
pathways activated by PDGFR phosphorylation are the Ras/mitogen-activated protein 
kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways (Figure 1.3). It is also 
important to note that these signaling pathways are tightly regulated by several 
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mechanisms that either attenuate or terminate the transmitted signal in order to prevent 
PDGFR dysfunction, including antagonistic ligands, tyrosine phosphatases and ligand-
induced receptor internalization and degradation (58). 
The Ras/MAPK pathway is highly conserved and plays pivotal roles in the control 
of proliferation, differentiation and cell migration (36). Upon PDGFR phosphorylation, 
the adaptor protein growth factor receptor-bound protein 2 (Grb2) binds to specific 
phosphotyrosine residues on the receptor through its SH2 domain and then recruits the 
guanine nucleotide exchange factor son of sevenless (Sos) to the membrane through its 
SH3 domain (58). The Grb2/Sos complex promotes the exchange of GDP for GTP on 
the small G protein Ras (58). Once in the active GTP-bound state, Ras first activates 
Raf, which in turn phosphorylates the S217 and S221 sites in the activation loop of 
mitogen-activated protein kinase kinases 1 and 2 (MEK1/2) (36). Activated MEK1/2 then 
phosphorylates the T202 and Y204 sites in the activation loop of extracellular signal-
related kinases 1 and 2 (ERK1/2) (36). Raf and ERK1/2 are serine/threonine protein 
kinases, while MEK1/2 is a serine/tyrosine/threonine protein kinase (36). As the final 
step in the Ras/MAPK pathway, activated ERK1/2 is translocated to the nucleus where 
it regulates the activities of several transcription factors via phosphorylation (58). 
 Activation of the PI3K pathway by PDGFRs promotes proliferation, cell survival, 
cell migration and cell growth (3). PI3K is a heterodimer that consists of the regulatory 
subunit p85, which contains two SH2 and one SH3 domain, and the catalytic subunit 
p110 (58). Upon PDGFR phosphorylation, PI3K binds to specific phosphotyrosine 
residues on the receptor and is responsible for the conversion of phosphatidylinositol 
4,5-bisphosphate (PIP2) to the second messenger phosphatidylinositol 3,4,5-
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trisphosphate (PIP3) (40). In contrast, phosphatase and tensin homolog (PTEN) 
catalyzes the dephosphorylation of PIP3 to PIP2, and as such, is a negative regulator of 
the PI3K pathway (58). Protein kinase B (Akt) is a serine/threonine protein kinase that 
binds PIP3 at the membrane through its N-terminal pleckstrin homology (PH) domain 
and is activated by phosphoinositide-dependent kinase-1 (PDK1) via phosphorylation at 
the T308 site in its activation loop (18). An additional S473 site on Akt can be 
phosphorylated by the mechanistic target of rapamycin complex 2 (mTORC2), and 
phosphorylation of both sites is required for full activation of Akt (38). Following its 
phosphorylation by PDK1, Akt is released into the cytosol where it acts on mTORC1 by 
inhibiting tuberous sclerosis proteins 1 and 2 (TSC1/2) (18). TSC2 contains a GTPase 
activating protein (GAP) domain that normally promotes the exchange of GTP for GDP 
on the small G protein Ras homolog enriched in brain (Rheb), but inhibition of TSC2 by 
Akt favors the active GTP-bound state of Rheb, and hence functions as an activator of 
mTORC1 (82). TSC1 does not have a GAP domain, but instead stabilizes TSC2 and 
likely prevents it from degradation (82). mTORC1 is a serine/threonine protein kinase 
that signals downstream through multiple signaling proteins including p70 S6 kinase 
(p70S6K) via phosphorylation at the T389 site in its linker domain (71). Additional T421 
and S424 sites in the pseudosubstrate domain of p70S6K can be phosphorylated by 
various upstream kinases, which lead to conformational changes that enhance the 
activation of p70S6K (71). Activated p70S6K increases protein synthesis by stimulating 
ribosomal protein S6 (rpS6) and eukaryotic translation initiation factor 4B (eIF4B), 
factors that increase ribosomal biogenesis and initiate mRNA translation, respectively 
(82). Finally, phosphorylation of eukaryotic translation initiation factor 4E-binding protein 
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1 (4EBP1) by mTORC1 releases its inhibition on eIF4E, which is bound to the 5’ cap 
structure of mRNA, and allows mRNA translation to proceed (82). 
In both mice and humans, PDGFs function as secreted hetero- or homodimers of 
disulfide-linked polypeptide chains (PDGF-AA, PDGF-BB, PDGF-CC, PDGF-DD and 
PDGF-AB) (3, 23, 24). All PDGFs contain a core domain with a conserved set of eight 
cysteine residues, which have been shown to be necessary and sufficient for receptor 
binding and activation (3). The PDGF-AB heterodimer can be found in human platelets, 
and while its physiological importance is still under debate, homodimers appear to be 
dominant form of PDGF ligands in vivo (3). Based on cell culture experiments, multiple 
PDGF-PDGFR interactions have been described in vitro, but functional evidence 
suggests the actual number of PDGF-PDGFR interactions in vivo is more limited. 
PDGF-AA and PDGF-CC bind to PDGFRαα, while PDGF-BB and PDGF-DD have a 
higher affinity for PDGFRββ (24). Differences in sequence structure and proteolytic 
processing between the PDGF ligands helps distinguish them from one another. The N-
terminal prodomains of PDGF-AA and PDGF-BB are removed intracellularly by furin 
convertases and each are secreted in its active form (15), while PDGF-CC and PDGF-
DD are secreted in their latent forms and require activation outside of the cell (15). 
Activation of PDGF-CC and PDGF-DD requires cleavage of their N-terminal 
complement subcomponents C1r/C1s, sea urchin uEGF and human BMP-1 (CUB) 
domains (24). The endogenous proteases responsible for the dissociation of the CUB 
domains from PDGF-CC and PDGF-DD have not been identified in vivo, although 
plasmin and tissue plasminogen activator (tPA) have been shown to accomplish this 
task in cell culture (16). Following secretion from the cell, PDGF-AA and PDGF-BB can 
	 20 
establish diffusion gradients in the interstitium by binding to various ECM components 
such as matrix proteoglycans due to their C-terminal retention motifs that contain a 
stretch of positively charged basic amino acid residues (3, 30). These motifs help retain 
the PDGF ligands in the ECM near the cells that produce them until they are released 
by paracrine factors such as thrombin (24, 70). Although PDGF-CC and PDGF-DD lack 
retention motifs, their CUB domains may regulate the extracellular distribution of these 
ligands through protein-protein interactions (3). With regard to tendon, the role of 
PDGFR signaling in tendon growth and injury has remained largely unexplored. While 
PDGFRα and PDGFRβ are mainly expressed by mesenchymal and perivascular cells, 
respectively, the expression pattern of PDGFRs by tendon fibroblasts is not known (3). 
In the case of tendon growth, it remains possible that the local bioavailability of PDGF 
increases by mechanical or proteolytic activation of latent PDGF in the tendon ECM 
similar to transforming growth factor beta (TGF-β) (20). However, in the event of tendon 
injury, PDGF secretion by infiltrating platelets and other inflammatory cells such as 
macrophages likely accounts for the paracrine effects of PDGF on tendon tissue (49). 
 
Dissertation Aims 
The main focus of this dissertation is to address a fundamental question in 
musculoskeletal biology – how do adult tendons grow? In response to physiological 
loading, adult tendon tissue increases in size and undergoes changes to its matrix 
composition, which ultimately leads to an increase in athletic performance. However, if 
loading is too much or too frequent, patients may develop tendinopathy as a result of 
cumulative damage to the tendon ECM. Given the relationship between tendon growth 
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and injury, insights gained from studies of the tendon growth are likely to facilitate a 
better understanding of tendon healing following injury. Therefore, the objective of this 
dissertation was to determine the role of key signaling pathways activated during tendon 
growth and injury, and to investigate the biological mechanisms behind these 
responses. Since a central feature of tendon disorders is abnormal fibroblast 
morphology and a grossly disrupted appearance of the tendon ECM, my overall working 
hypothesis is molecular programs that regulate the interaction between tendon 
fibroblasts and their local ECM environment during tendon growth play an important role 
in the healing response of injured tendons. In Chapter II, transection of the Achilles 
tendon followed by acute repair is accompanied by significant changes in the tendon 
transcriptome, including upregulation of numerous matrix metalloproteinase (MMP) and 
epithelial-to-mesenchymal transition (EMT) genes, many of which are known to be 
regulated by PDGFR signaling. PDGFs have been investigated as a potential form of 
treatment in translational studies to enhance tendon healing following injury. They have 
been used with modest success in canine models of intrasynovial flexor tendon repair 
(73, 74), and their use improved mechanical properties in a rat model of Achilles 
tendinopathy induced by collagenase injection compared to other common treatments, 
including platelet-rich plasma and steroids (64). However, most of the previous work on 
PDGF function in tendon is correlative. This dissertation makes a substantial 
contribution to the literature by testing the importance of PDGFR signaling in the context 
of tendon growth with loss of function experiments. In Chapter III, the inhibition of 
PDGFR signaling suppressed the normal growth of tendon tissue after mechanical 
overload due to defects in fibroblast proliferation and migration, and membrane type-1 
	 22 
matrix metalloproteinase (MT1-MMP) was identified as an essential proteinase for 
fibroblast migration through tendon ECM. Taken together, these findings demonstrate 
that PDGFR signaling is necessary for postnatal tendon growth and remodeling, and 
that MT1-MMP is a critical mediator of tendon fibroblast migration and a potential target 
for the treatment of tendon injuries and diseases.  
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Figure 1.1. Tendon stress-strain curve (78). 
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Figure 1.2. Graphical representation of the morphological features in healthy tendon 
and tendinopathy. Modified from Scott et al (62). 
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Figure 1.3. Overview of the major signaling pathways activated by PDGFR 
phosphorylation. Modified from Gumucio et al (18). 
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Chapter II 
 
Changes in Macrophage Phenotype and Induction of Epithelial-to-Mesenchymal 
Transition Genes Following Acute Achilles Tenotomy and Repair 
 
Abstract 
Tendon injuries occur frequently in physically active individuals, but the clinical 
outcomes for these injuries can be poor. In many injured tissues the repair process is 
orchestrated by two types of cells, macrophages and fibroblasts. Macrophages, which 
have both pro-inflammatory (M1) and anti-inflammatory (M2) phenotypes, can directly 
participate in tissue remodeling and direct the response of other cells through the 
secretion of cytokines and growth factors. In many organ systems, epithelial cells can 
transdifferentiate into fibroblasts, which can then regenerate damaged ECM. This 
process is triggered via activation of epithelial-to-mesenchymal transition (EMT) 
signaling programs. Most tendons are surrounded by sheets of epithelial cells, and 
these tissue layers could provide a source of fibroblasts to repair injured tendons. To 
gain greater insight into the biology of tendon repair, we performed a tenotomy and 
repair in Achilles tendons of adult rats and determined changes in macrophage 
phenotype and ECM- and EMT-related genes over a 4-week time course. The results 
from this study suggest that changes in macrophage phenotype and activation of EMT-
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related programs likely contribute to the degradation and subsequent repair of injured 
tendon tissue. 
 
 Introduction 
Tendon is a dynamic tissue that promotes efficient force transmission and drives 
locomotion by connecting muscle to bone. Injuries and diseases of tendons produce 
significant morbidity in patients, including debilitating pain and a decrease in functional 
capacity (48). While the etiology of tendon injury remains unclear, the accumulation of 
degenerative changes in the tendon extracellular matrix (ECM) over time predisposes 
the patient to spontaneous tendon rupture (48, 58). Repetitive microtrauma is thought to 
overwhelm the ability of tendon fibroblasts to repair the injured ECM network, and this 
likely leads to variegated cellularity, increased vascular elements and collagen fibril 
disorganization(9, 48). Indeed, degenerative tendinopathy is the most common 
histological finding at the site of tendon rupture, and reversal of this process can be 
challenging because tendons are particularly slow to heal (21). Accordingly, the 
management of tendon injuries is an exigent task for clinicians, and in many cases, 
patients remain symptomatic despite optimal therapy (58). In order to improve the 
treatment of tendon injuries, a greater understanding of the cellular and molecular 
factors that drive tendon healing is required. 
In many injured tissues, the repair process proceeds through three overlapping 
stages, described as the inflammatory, proliferative and remodeling phases (17, 58). 
Although numerous cell types play important roles in tendon healing, the repair of 
injured tendon tissue is thought to be orchestrated by two types of cells, macrophages 
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and fibroblasts (48). Following the initial recruitment of neutrophils to the site of injury, 
an accumulation of macrophages is observed in the tendon ECM within the first 24 
hours (33). Macrophages participate in the phagocytic removal of necrotic debris, but 
eventually shift their function to promote fibroblast proliferation and guide ECM 
remodeling through the release of chemotactic and growth factors (12, 17, 26, 58). 
Macrophages have two general phenotypes – classically activated pro-inflammatory 
macrophages (M1) that promote ECM breakdown, inflammation and apoptosis; and 
alternatively activated anti-inflammatory macrophages (M2) that coordinate ECM 
deposition and tissue repair (25, 49). Previous work in damaged skeletal muscle has 
demonstrated that suppression of either M1 or M2 macrophage function severely 
impairs tissue regeneration, indicating the important balance between inflammation and 
regeneration for proper tissue repair (31). 
Fibroblasts are the predominant cell type in tendons and are responsible for the 
development, maintenance, repair and modification of the tendon ECM (24). In 
response to tissue injury, fibroblasts synthesize ECM proteins, including collagens, 
proteoglycans and glycoproteins (24). Fibroblasts also release matrix 
metalloproteinases (MMPs), a family of zinc-dependent enzymes that selectively 
degrade various components of the ECM network, and their endogenous inhibitors, 
tissue inhibitors of metalloproteinases (TIMPs) (9). The levels of MMPs and TIMPs 
fluctuate throughout the repair process, which culminates in the eventual replacement of 
the damaged tendon ECM with newly synthesized collagen and non-collagenous 
proteins (24, 48, 58). Previous work has demonstrated that the epitenon, a loose 
epithelial-like tissue layer that surrounds the tendon, may serve as a source of 
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fibroblasts contributing to tendon growth and repair (35, 53). In other organ systems, 
reactivation of one or more members of the Snail family of transcription factors 
promotes the transdifferentiation of epithelial cells to a mesenchymal cell lineage 
through a process known as epithelial-to-mesenchymal transition (EMT) (19, 23, 27). 
Once in the mesenchymal lineage, the cells adopt a fibroblast phenotype, and begin 
remodeling and synthesizing new ECM (19, 23, 27). While EMT plays an important part 
in the regeneration of other tissues, the role of the EMT process in tendon repair has 
not been previously described. 
To gain greater understanding of the fundamental cellular and molecular biology 
of tendon repair, we performed a tenotomy and repair in Achilles tendons of adult rats 
and analyzed changes in macrophage phenotype and ECM- and EMT-related genes. 
Tissue was harvested at 3, 7, 14 and 28 days after injury and compared to uninjured 
controls. We hypothesized that in response to a full-thickness tear of the Achilles 
tendon there would be an early accumulation of M1 macrophages within the first week 
followed by gradual transition to the M2 phenotype, and that tendon repair would 
correlate with increased expression of EMT-related genes. 
 
Methods 
Animals and Surgical Procedure. The University of Michigan IACUC approved 
this study. Six-month-old male Sprague–Dawley rats were randomized to control, 3-, 7-, 
14- or 28-day groups (N=6 rats per group). Tendon surgery was performed on both 
Achilles tendons. Rats were anesthetized with 2% isoflurane, and the skin overlying the 
surgical site was shaved and scrubbed with 4% chlorhexidine. A midline incision was 
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created in the skin and the paratenon was split to achieve visualization of the Achilles 
tendon. A full-thickness tenotomy was performed in the midsubstance of the tendon 
followed by immediate two-strand repair using the Bunnell technique with 5-0 Ethibond 
(Ethicon, Somerville, NJ) (Figure 2.1). The plantaris tendon was left intact. The 
paratenon was loosely re-approximated and the skin closed using 4-0 Vicryl (Ethicon) 
and GLUture (Abbott, Abbott Park, IL). A splash block of 0.5 ml of 0.5% bupivacaine, 
buprenorphine (0.05 mg/kg) and carprofen (5 mg/kg) were administered for analgesia 
during postoperative recovery. Ad libitum weight-bearing and cage activity were 
allowed. At harvest, rats were anesthetized with pentobarbital (50 mg/kg) and Achilles 
tendons were harvested for either gene expression analysis or immunohistochemistry 
(IHC). Achilles tendons were also collected from rats that did not undergo tenotomy and 
served as controls. After the removal of tendons, animals were euthanized by 
anesthetic overdose and induction of bilateral pneumothorax. 
Gene Expression. The right Achilles tendon was homogenized in QIAzol 
(Qiagen, Valencia, CA). RNA was isolated using a miRNeasy Kit (Qiagen), treated with 
DNase I (Qiagen) and reverse transcribed into cDNA using oligo-dT15 and random 
hexamer primers with the RT2 Kit (Qiagen). cDNA was amplified in a CFX96 real-time 
thermal cycler (Bio-Rad, Hercules, CA) using a QuantiTect SYBR Green (Qiagen). The 
methods of Livak and Schmittgen (44) were used to normalize target gene expression 
to the stable housekeeping gene β2-microglobulin (B2M). Transcript information and the 
specific function of each gene are provided in Table 2.1. 
Immunohistochemistry. Left Achilles tendons were isolated, snap frozen in TFM 
(Triangle Biosciences, Durham, NC), and stored at -80°C. Tendons were sectioned 
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through the callus at a thickness of 10 µm in a cryostat. Slides were fixed in 4% 
paraformaldehyde, permeabilized in 0.2% Triton X-100 and blocked with 5% goat 
serum. Slides were incubated with primary antibodies against rabbit anti-CCR7 (NB110-
55680, Novus Biologicals, Littleton, CO) and mouse anti-CD163 (MCA342B, AbD 
Serotec, Raleigh, NC) to label M1 and M2 macrophages, respectively (2, 7). Alexa Fluor 
555 (AF555, Life Technologies, Eugene, OR) secondary antibodies or streptavidin-
AF647 were used to detect primary antibodies. DAPI was used to identify nuclei and 
ECM was labeled with WGA-lectin conjugated to AF488 (Life Technologies). Slides 
were mounted and imaged using a Zeiss Axiovert 200M outfitted with the ApoTome 
system (Carl Zeiss, Thornwood, NY). 
Statistical Analyses. Results are presented as mean±SE. Prism 6.0 software 
(GraphPad Software, La Jolla, CA) was used to conduct analyses. A one-way ANOVA 
(α=0.05) followed by Tukey’s post hoc sorting was performed to determine significance 
between groups. 
 
Results 
Control tendons demonstrated the presence of M2 and occasional M1 
macrophages in the endotenon layers, but no macrophages in the tendon fibers (Figure 
2.2A). Three days following surgical tear and repair, M1 macrophages accumulated in 
regions of newly formed tendon tissue and remained present throughout the study 
period (Figure 2.2B-E). M2 macrophages slowly accumulated at sites of organizing 
tendon ECM and became the predominant macrophage phenotype by 28 days (Figure 
2.2E). In most cases, after injury macrophages were localized in areas of tissue 
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resorption as indicated by the lack of WGA staining. The change in M1 and M2 signal 
present in IHC was accompanied by quantitative changes in gene expression. For 
genes that regulate macrophage and neutrophil function (Figure 2.3), the neutrophil 
marker Ly6c was elevated by 3 days, but returned to levels similar to controls by 28 
days. The pan-macrophage marker F4/80 was also elevated by 3 days. However, after 
an initial decline at 7 days, it remained elevated compared to controls thereafter. CCL2, 
which plays an important role in macrophage recruitment, was elevated by 3 days and 
then steadily declined over the next few weeks. Markers of M1 macrophages such as 
CD68, CCR7 and CD11b were dramatically elevated following surgical tear and repair. 
CD68 and CD11b declined between 3 and 7 days. CD168, a marker for M2 
macrophages, remained similar to controls until day 28 at which time it became 
significantly elevated. Pro-inflammatory interleukins IL1b and IL6 were up-regulated by 
3 days, but IL6 demonstrated a gradual decline in expression between each time point. 
Upregulation of the anti-inflammatory interleukin IL10 did not occur until 28 days. 
For fibroblast proliferation and cell cycle control factors (Figure 2.4), the type II 
transmembrane protein tenomodulin (Tnmd) promotes tendon fibroblast proliferation 
and was significantly downregulated by 3 days. It was then elevated compared to 
controls by 7 days with peak expression at 14 days. Scleraxis (Scx), a bHLH 
transcription factor involved in tendon development, was elevated by 7 days with a 
slight decline in expression at 28 days. Alpha smooth muscle actin (SMA) is an indicator 
of fibroblast contractility and was elevated at 7 days, but quickly returned to levels 
similar to controls by 14 days. No changes in the pan-fibroblast marker FSP1 were 
noted at any time point. Moreover, no differences in Mohawk (Mkx) expression, a 
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marker of tendon maturation, were observed. HIF1a serves as a gauge of tissue 
hypoxia and was elevated by 3 days with further increases in expression at 7 and 14 
days. Egr1 and Egr2, transcriptional regulatory proteins that are induced by various 
mitogenic cues, were elevated by 7 days. While Egr1 returned to levels similar to 
controls by 14 days, Egr2 remained elevated for the remainder of the study period. The 
cellular differentiation marker Aatk remained similar to controls until day 28 at which 
time its expression was upregulated. 
For EMT-related genes (Figure 2.5), the transcription factors Snail1 (Snai1) and 
Slug were elevated by 3 days and then declined by either 14 or 28 days, respectively. 
Goosecoid (Gsc), a homeobox protein that induces EMT, was elevated at 7 and 14 
days compared to controls. Twist1, a bHLH transcription factor that also induces EMT, 
was elevated by 7 days and returned to baseline levels by 28 days. No differences in 
expression of the angiogenic factor VEGF or the transcription factor Foxc2, which is 
induced by EMT events, were noted at any time point. The endothelial cell marker CD31 
was elevated at 7 days and the cell adhesion molecule E-cadherin (Cdh1) was 
significantly upregulated at 28 days. Ddr2, an EMT-responsive receptor tyrosine kinase, 
was downregulated by 3 days, but returned to levels similar to controls by 7 days. 
For ECM gene expression (Figure 2.6), the small leucine-rich proteoglycan 
(SLRP), biglycan (Bgn), and the cartilage-specific proteoglycan aggrecan (Acan) were 
significantly elevated by 3 and 7 days, respectively. Both remained elevated with a 
slight decrease between 14 and 28 days. In contrast, the SLRPs decorin (Dcn), and 
fibromodulin (Fmod) were downregulated by 3 days, and only Fmod returned to levels 
similar to controls by 7 days. The intermediate filament vimentin (Vim) was briefly 
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upregulated at 7 days, while the large proteoglycan versican (Vcan) was significantly 
expressed by 3 days and then steadily declined. Collagen type I (Col1a1) and type III 
(Col3a1) were both upregulated by 3 days with peak expression at 7 days. Members of 
the MMP family displayed similar levels of expression with upregulation of MMP2, 
MMP3, MMP8 and MMP14 by 3 days, and MMP9 by 7 days. MMP2, MMP8 and 
MMP14 were maximally expressed at 14 days and declined thereafter, while MMP9 
steadily increased over the next few weeks. TIMP1 was elevated by 3 days and then 
declined by 14 days, whereas TIMP2 was elevated by 7 days with peak expression at 
14 days. 
 
Discussion 
While tendon injuries are common and can significantly detract from the quality of 
life, compared with other musculoskeletal tissues little is known about the biology of 
tendon repair. This was the first study, to our knowledge, that identified changes in 
canonical EMT-related genes over the course of tendon injury and repair. Further, we 
report changes in different populations of macrophages, and in fibroblast proliferation 
and ECM synthesis genes that play important structural and mechanical roles in tendon. 
There appears to be overlapping activation of various gene families within the first four 
weeks of tendon repair, and EMT-related factors may contribute to the repair process in 
injured tendon tissue. 
In response to structural damage, chemotactic cytokines that promote the 
delivery of different cell populations to the repair site are released from the tendon ECM 
(9, 24). Phagocytic neutrophils and M1 macrophages are the first to arrive within 24 
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hours after injury, followed by a reparative shift in function that correlates with increases 
in M2 macrophages (17, 48, 58). Using ED1 (CD68) and ED2 (CD163) to identify pro- 
and anti-inflammatory macrophages, respectively, Marsolais et al. (33) found that 
following the injection of collagenase into tendons, there was a rapid accumulation of 
M1 macrophages that returned to baseline levels two weeks after injury. No significant 
change in M2 macrophages was detected over the course of the study. In a study that 
explored early mechanical loading after collagenase injection into tendons, Godbout et 
al. (14) reported an increase in M1 macrophages that was similar to Marsolais et al. 
(33), but also that exercise increased M2 macrophages three days after injury. The 
results of the current study are consistent with previous work as evidenced by 
upregulation of M1 markers CD68, CCR7 and CD11b as well as interleukins IL1b and 
IL6 within 72 hours. These pro-inflammatory factors remained consistently elevated at 
each time point, while the M2 marker CD168 and interleukin IL10 were not induced until 
28 days. Similar observations in the early M1 response were found in injured skeletal 
muscle using a model of reloading after hindlimb suspension (51, 55). Following 
resumption of weight-bearing, M1 macrophages precipitously accumulate in the 
reloaded muscle within 48 hours, but expression was more transient with the M1 signal 
returning to levels similar to controls within one week post-injury. Although M2 
macrophages also appeared at much earlier time points, the sequential transition 
between the M1 and M2 phenotypes supports the dual functionality of this cell type in 
the degradation and repair of injured tendons. 
Following connective tissue injury, there is a pronounced early increase in the 
number of macrophages and fibroblasts (48). While tendon fibroblasts are thought to 
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come from either a circulating pool of bone marrow-derived progenitor cells or from 
resident populations of tendon stem/progenitor cells (4), a growing body of evidence in 
other tissues suggests that resident cells in the host epithelium become activated and 
undergo an EMT transcriptional reprogramming to a mesenchymal fibroblast phenotype 
(19, 23). As cells undergo EMT, they experience a loss of epithelial-associated 
junctional complexes, begin to express mesenchymal cell markers and acquire tissue-
invasive properties that allow them to transmigrate their basement membrane and move 
into different environments. The epitenon is an epithelial structure subtended by a 
basement membrane (53), and prior work in in vitro and in vivo models of lacerated 
flexor tendons has demonstrated that fibroblasts migrate from this outer layer into the 
site of tendon injury (13, 22, 32, 53), as well as in response to treadmill training (35). In 
the present study, we found that following acute Achilles tenotomy and repair there was 
a significant upregulation of canonical EMT-related genes including Snail1, Slug, 
Goosecoid and Twist1. These transcription factors repress cell adhesion proteins and 
induce metalloproteinases that degrade the ECM and promote tissue invasion (37). 
Accompanying these changes were increased expression of mesenchymal tendon 
fibroblast markers scleraxis and tenomodulin, as well as ECM-remodeling enzymes 
MMP2, MMP3, MMP8, MMP9 and MMP14, and their endogenous inhibitors TIMP1 and 
TIMP2. Consistent with these results, other models of Achilles tendon injury have 
demonstrated massive increases in the expression of tendon-specific markers (11, 20). 
Moreover, Scott and colleagues (46) found that scleraxis, tenomodulin and type I 
collagen were significantly expressed in an injured mouse patellar tendon 4 weeks after 
a central defect was surgically created. Scleraxis and type I collagen expression 
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eventually returned to baseline levels, but tenomodulin remained elevated even at 12 
weeks post-injury. Induction of MMP expression has also been shown to correlate with 
collagen turnover and ECM remodeling during tendon repair (9, 40). Further, 
proteoglycans are important regulators of collagen fibril assembly and variations in their 
content can greatly alter tendon structure and function (10). Following surgical tear and 
repair of the Achilles tendon, we observed an upregulation of type I and III collagens, 
aggrecan, biglycan and versican, and a downregulation of decorin and fibromodulin. 
The reduction in decorin expression is supported by previous studies that demonstrated 
decreased rates of collagen fibrillogenesis in vitro in the presence of decorin (8, 57). In 
addition to abnormal fibril structure and impaired mechanical function, decorin-deficient 
tendons display an increase in biglycan expression (60). This may compensate for the 
loss of decorin as biglycan is expressed during early tendon development, but its 
expression normally declines as the tendon matures (1). Similar to the altered tendon 
phenotype described in decorin-null mice, a deficiency of fibromodulin also produces 
tendons with thin, irregular collagen fibrils (52). Aggrecan is a proteoglycan, that is 
expressed during later stages of chondrogenesis, and is also expressed in regenerating 
tendons following tenotomy (29). Increased expression of aggrecan is correlated with 
the induction of heterotopic ossification in injured tendons (29), and although we did not 
directly measure other markers of osteogenesis, the increase in aggrecan at later time 
points suggests some heterotopic ossification was also occurring in our model. Overall, 
findings from this study in conjunction with previous work suggest that the assembly of 
the collagen network during tendon repair may be mediated by the temporal-specific 
expression of proteoglycans. 
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This study provided important insights into changes in macrophage phenotype 
and EMT-related genes following acute Achilles tenotomy and repair, but there are 
several limitations. We did not immobilize the hindlimbs postoperatively, which is 
standard practice in patients undergoing Achilles tendon repairs. However, the plantaris 
tendon was left intact, and as the plantaris tendon is substantially larger in rats than 
humans, this likely provides stress shielding for the injured Achilles tendon. Immediate 
mobilization at the repair site may have impacted the amount of inflammation present, 
but should not have altered the sequence of inflammatory cell accumulation within the 
injured tissue. We also focused only on the Achilles tendon and the observed 
differences may not be reflected in trunk or other limb tendons. While there are 26 
known MMP genes (9), we evaluated only a subset of MMPs that were selected from 
the four general classes of MMPs. Our animal model is most representative of acute 
tendon transections, and may not recapitulate longstanding degenerative changes in 
the tendon ECM. Finally, in addition to driving transdifferentiation and migration through 
the EMT program, Snail1, Slug, Goosecoid and Twist1 have other EMT-independent 
functions including cell lineage specification, cell cycle regulation, apoptosis, and both 
ECM synthesis and remodeling (3, 41, 47, 56). While these results are encouraging, 
whether EMT is truly occurring in tendon, or fibroblasts emerging from the epitenon are 
simply proliferating populations of resident cells, remains to be determined. Further 
studies are needed to decipher the specific roles of these genes during tendon repair. 
This study evaluated changes in the expression of EMT-related genes during the repair 
of injured tendon tissue, but changes in the levels of specific proteins were not 
investigated. However, previous studies in other tissues have demonstrated that 
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changes in the expression of specific EMT-related genes correlate with changes in the 
abundance of the translated proteins (34, 42). 
Injuries to and diseases of tendons are a substantial economic and health burden 
among patients of all ages. Nonoperative interventions focus on symptomatic relief, and 
even with surgery patients may have poor outcomes and continue to experience pain 
and reduced function (48). A more direct approach to the management of tendon 
injuries is needed, and the current lack of targeted therapies is due in part to our limited 
mechanistic insight into basic physiological processes that control tendon repair. 
Findings from this study and from Marsolais et al. (33) demonstrate that macrophages 
change phenotype in response to tendon damage and this likely contributes to the 
degradation and subsequent repair of injured tendon ECM. Further investigation of the 
specific functions of macrophage sub-populations in tendon is therefore warranted. 
Lastly, given the critical role EMT plays in the postnatal growth of many tissues in the 
body and in pathologic conditions such as tissue fibrosis, the expression of EMT-related 
genes during tendon repair may prove to be a worthwhile area of scientific exploration. 
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Figure 2.1. llustration of tendon repair. A full-thickness tenotomy was performed in the 
midsubstance of the Achilles tendon and the plantaris tendon was left intact. The defect 
was then repaired immediately using a two-strand core suture (Bunnell technique).  
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Figure 2.2. Macrophages accumulate sequentially in tendon following surgical tear and 
repair. M2 macrophages are found in the endotenon of (A) nonoperated controls, but 
not in the tendon fibers. There is a dramatic accumulation of M1 macrophages in 
regions of ECM resorption that remained consistent in the (B) 3-day, (C) 7-day and (D) 
14-day groups. M2 macrophages become the predominant phenotype by (E) 28 days. 
M1 macrophages (CCR7), red (and indicated by red arrowheads); M2 macrophages 
(CD163), yellow (and indicated by yellow arrowheads); ECM (WGA-lectin), green; nuclei 
(DAPI), blue. Asterisks indicate areas of tissue resorption. All panels are shown at the 
same level of magnification as in panel A. 
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Figure 2.3. Changes in gene expression of macrophage and neutrophil markers in the 
Achilles tendon following surgical tear and repair. Target genes were normalized to B2M 
expression, and further normalized to the control group. Differences were tested using a 
one-way ANOVA (α=0.05) followed by Tukey’s post hoc sorting. (a) Different from 
control, (b) different from 3D, (c) different from 7D and (d) different from 14D. N=6 
tendons per group.  
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Figure 2.4. Changes in gene expression of fibroblast proliferation and cell cycle control 
factors in the Achilles tendon following surgical tear and repair. Target genes were 
normalized to B2M expression, and further normalized to the control group. Differences 
were tested using a one-way ANOVA (α=0.05) followed by Tukey’s post hoc sorting. (a) 
Different from control, (b) different from 3D, (c) different from 7D and (d) different from 
14D. N=6 tendons per group. 
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Figure 2.5. Changes in gene expression of EMT-related genes in the Achilles tendon 
following surgical tear and repair. Target genes were normalized to B2M expression, 
and further normalized to the control group. Differences were tested using a one-way 
ANOVA (α=0.05) followed by Tukey’s post hoc sorting. (a) Different from control, (b) 
different from 3D, (c) different from 7D and (d) different from 14D. N=6 tendons per 
group.  
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Figure 2.6. Changes in gene expression of ECM components and MMPs in the Achilles 
tendon following surgical tear and repair. Target genes were normalized to B2M 
expression, and further normalized to the control group. Differences were tested using a 
one-way ANOVA (α=0.05) followed by Tukey’s post hoc sorting. (a) Different from 
control, (b) different from 3D, (c) different from 7D and (d) different from 14D. N=6 
tendons per group. 
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mRNA Description / Purpose RefSeq No. 
Macrophage / Neutrophil 
Ly6c Ly6-C antigen / Neutrophil marker (36) NM_020103 
CCL2 Chemokine (C-C motif) ligand 2 / Macrophage recruitment marker (38) NM_031530 
F4/80 EGF-like module-containing mucin-like hormone receptor-like 1 / Pan-
macrophage marker (16) 
NM_001007557 
CD68 Cd68 molecule / M1 macrophage marker (16) NM_001031638 
CCR7 Chemokine (C-C motif) receptor 7 / M1 macrophage marker (16) NM_199489 
CD11b Integrin alpha M / M1 macrophage marker (16) AF268593 
CD168 Hyaluronan-mediated motility receptor (RHAMM) / M2 macrophage marker (16) NM_012964 
IL1b Interleukin 1 beta / Pro-inflammatory marker (16) NM_031512 
IL6 Interleukin 6 / Pro-inflammatory marker (16) NM_012589 
IL10 Interleukin 10 / Anti-inflammatory marker (16) NM_012854 
   
Fibroblast Proliferation / Cell Cycle Control 
Aatk Apoptosis-associated tyrosine kinase / Cellular differentiation marker (39) NM_001168703 
SMA Alpha-smooth muscle actin / Marker of fibroblast contractility (61) NM_031004 
Egr1 Early growth response 1 / Transcriptional regulatory protein (15) AY551092 
Egr2 Early growth response 2 / Transcriptional regulatory protein (28) NM_053633 
HIF1a Hypoxia-inducible factor 1, alpha subunit / Tissue hypoxia marker (61) NM_024359 
FSP1 Fibroblast specific protein 1, S100 calcium-binding protein A4 / Pan-fibroblast 
marker (54) 
NM_012618 
Tnmd Tenomodulin / Marker of tendon fibroblast proliferation (35) NM_022290 
Scx Scleraxis / Marker of tendon development (35) NM_001130508 
Mkx Mohawk homeobox / Marker of tendon maturation (18) XM_001063892 
   
EMT-Related Genes 
CD31 Platelet endothelial cell adhesion molecule 1 / Endothelial cell marker (61) NM_031591 
Cdh1 Cadherin 1, E-cadherin / Epithelial cell adhesion molecule (37) NM_031334 
Ddr2 Discoidin domain receptor tyrosine kinase 2 / EMT-responsive receptor tyrosine 
kinase (59) 
NM_031764 
Gsc Goosecoid homeobox / Homeobox protein (37) NM_001191873 
Snai1 Snail homolog 1 (Drosophila) / Zinc-finger transcription factor (37) NM_053805 
Slug Snail homolog 2 (Drosophila) / Zinc-finger transcription factor (37) NM_013035 
Twist1 Twist homolog 1 (Drosophila) / bHLH transcription factor (37) NM_053530 
VEGF Vascular endothelial growth factor A / Angiogenic factor (61) NM_031836 
Foxc2 Forkhead box C2 / Forkhead box transcription factor (30) NM_001101680 
   
ECM Components / MMPs 
Acan Aggrecan / Cartilage-specific proteoglycan (29) NM_022190 
Bgn Biglycan / Small leucine-rich proteoglycan (SLRP) (4) NM_017087 
Col1a1 Type I collagen / Mature collagen marker (9) NM_053304 
Col3a1 Type III collagen / Immature collagen marker (9) NM_032085 
Dcn Decorin / Small leucine-rich proteoglycan (SLRP) (10) NM_024129 
Fmod Fibromodulin / Small leucine-rich proteoglycan (SLRP) (4) NM_080698 
Vcan Versican / Large proteoglycan (45) NM_001170558 
Vim Vimentin / Intermediate filament (5) NM_031140 
MMP2 Matrix metalloproteinase 2 / Gelatinase A (9) NM_031054 
MMP3 Matrix metalloproteinase 3 / Stromelysin-1 (50) NM_133523 
MMP8 Matrix metalloproteinase 8 / Collagenase-2 (50) NM_022221 
MMP9 Matrix metalloproteinase 9 / Gelatinase B (9) NM_031055 
MMP14 Matrix metalloproteinase 14 / Membrane-tethered type-1 matrix 
metalloproteinase (9) 
NM_031056 
TIMP1 Tissue inhibitor of metalloproteinase 1 / Inhibitor of secreted MMPs (43) NM_053819 
TIMP2 Tissue inhibitor of metalloproteinase 2 / Inhibitor of secreted and membrane-
anchored MMPs (43) 
NM_021989 
   
Housekeeping   
B2M Beta-2 microglobulin / Component of class I MHC molecules (6) NM_012512 
 
Table 2.1. mRNA transcripts evaluated by quantitative PCR. 
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Chapter IIII 
 
Postnatal Tendon Growth and Remodeling Requires Platelet-Derived Growth 
Factor Receptor Signaling 
 
Abstract 
Platelet-derived growth factor receptor (PDGFR) signaling plays an important 
role in the specification and fundamental biological activities of many cells that compose 
musculoskeletal tissues, although little is known about PDGFR signaling during tendon 
growth and remodeling in vivo. Using the hindlimb synergist ablation model of tendon 
growth, our main objective was to determine the role of PDGFR signaling in the 
adaptation of tendons subjected to a mechanical growth stimulus, as well as to 
investigate the biological mechanisms behind this response. We demonstrate that both 
PDGFRs, PDGFRα and PDGFRβ, are expressed in tendon fibroblasts, and that the 
inhibition of PDGFR signaling suppresses the normal growth of tendon tissue after 
mechanical overload due to defects in fibroblast proliferation and migration. We also 
identify membrane type-1 matrix metalloproteinase (MT1-MMP) as an essential 
proteinase for fibroblast migration through tendon extracellular matrix. Furthermore, we 
show that MT1-MMP translation is regulated by PI3K/Akt, while ERK1/2 controls post-
translational trafficking of MT1-MMP within tendon fibroblasts. Taken together, these 
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findings demonstrate that PDGFR signaling is necessary for postnatal tendon growth 
and remodeling, and that MT1-MMP is a critical mediator of tendon fibroblast migration 
and a potential target for the treatment of tendon injuries and diseases. 
 
Introduction 
Tendon is an integral component of the musculoskeletal system. Anatomically 
situated between skeletal muscle and bone, tendon transmits and stores force, allowing 
for efficient locomotion. The function of tendon is determined by the biochemical 
composition and macromolecular structural organization of its extracellular matrix 
(ECM), which consists of a dense network of cross-linked type I collagen with smaller 
amounts of type III collagen, elastin and various proteoglycans (22). This collagen-rich 
tissue provides structural support to the tendon, selectively binds and releases growth 
factors that regulate multiple cellular functions, and organizes the compartments that 
contain various cell populations (5). Tendon fibroblasts are the predominant cell type in 
tendon, and are responsible for the production, maintenance, modification and repair of 
matrix proteins (22). Despite the importance of tendon to the overall function of the 
musculoskeletal system, relatively little is known about the cellular and molecular 
mechanisms that regulate tendon growth and remodeling in the adult.  
Tendon adapts to increased mechanical loads by undergoing hypertrophy, as 
evidenced by increases in tendon cross-sectional area (CSA), cell density, peak stress, 
peak strain and type I collagen content (9, 27, 43). While the specific growth factors and 
signaling pathways required for this process are largely unknown, one family of growth 
factors that are upregulated following tendon injury and are active at multiple stages of 
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the healing process are the platelet-derived growth factors (PDGFs) (29, 55). PDGFs 
typically function as secreted hetero- or homodimers of disulfide-linked polypeptide 
chains (PDGF-AA, PDGF-BB, PDGF-CC, PDGF-DD and PDGF-AB) (1, 12, 14), with 
PDGF-BB among the most frequent PDGF isoforms used to enhance regeneration in 
various animal models of tendon injury (23, 54). PDGFs bind to and activate a class of 
structurally related receptor tyrosine kinase transmembrane proteins known as PDGF 
receptors α (PDGFRα) and β (PDGFRβ) (1, 12, 14). Upon binding to their ligands, 
PDGFRs dimerize (αα, αβ and ββ) and undergo autophosphorylation of conserved 
cytoplasmic tyrosine residues that initiate multiple signal transduction cascades, 
including the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) and extracellular 
signal-related kinases 1 and 2 (ERK1/2) pathways (14). PDGFs are potent mitogens 
and their signaling events control key biological functions in many cell types of 
mesenchymal origin, including proliferation, differentiation, migration and ECM 
synthesis and remodeling (1, 14, 46). While PDGFs are expressed in tendon tissue, the 
identity and tissue localization of PDGFRα+ and PDGFRβ+ cells in tendon have not 
been clearly defined, and the overall importance of PDGFR signaling to the growth 
response of mechanically loaded tendons is presently unknown.  
 During periods of tendon growth and remodeling, fibroblasts express matrix 
metalloproteinases (MMPs), a family of zinc-dependent endopeptidases that collectively 
degrade multiple ECM components, including type I collagen (5, 43). Membrane-type 
MMPs (MT-MMPs) are a sub-class of MMPs that allow cells to migrate through their 
respective ECMs, by constraining type I collagen degradation to the leading edge of the 
cell membrane (8, 16). Within the MT-MMP subgroup, membrane type-1 MMP (MT1-
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MMP) is required for proper tendon development, as the deletion of MT1-MMP in 
embryonic tendon fibroblasts results in the failure of normal tendon formation (51). MT1-
MMP expression has also been shown to correlate with pivotal events in the growth 
response of mechanically-loaded tendons of adult animals (43). In other cell types, 
MT1-MMP expression is regulated by receptor tyrosine kinase signaling, (13, 48), but 
the signal transduction pathways that regulate MT1-MMP expression in tendon 
fibroblasts are not known.  
Given that PDGFs are expressed in tendon, and that MT1-MMP is important for 
tendon development, we sought to determine the role of PDGFR signaling in postnatal 
tendon growth and remodeling. We hypothesized that inhibition of PDGFR signaling 
would suppress the normal growth of tendon tissue during mechanical overload due to 
defects in cell proliferation and migration. To test this hypothesis, we induced tendon 
growth in adult mice via mechanical overload using the hindlimb synergist ablation 
model, and blocked PDGFRα and PDGFRβ signaling through the use of a 
pharmacological inhibitor. We also conducted a series of in vitro experiments to 
determine the molecular mechanisms that underlie the PDGFR-dependent growth of 
tendons in adult animals.  
 
Methods 
Mice. All animal studies were approved by the University of Michigan Institutional 
Animal Care & Use Committee. Wild-type (WT) C57BL/6 mice and transgenic 
PDGFRαeGFP/+ mice were obtained from the Jackson Laboratory (Bar Harbor, ME, 
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USA). PDGFRαeGFP/+ mice express the H2B-eGFP reporter gene from the endogenous 
PDGFRa locus (10). Four-month-old male mice were used in all experiments. 
 Synergist Ablation. Mice were randomized to 3- and 10-day groups. Bilateral 
synergist ablation procedures were performed under isoflurane anesthesia as described 
previously (9, 46). An overview is presented in Figure 1A. The Achilles tendon was 
surgically excised to prevent the gastrocnemius and soleus muscles from plantarflexing 
the talocrural joint, resulting in compensatory hypertrophy of the synergist plantaris 
musculotendinous unit. Buprenorphine was administered for post-operative analgesia, 
and ad libitum weight-bearing and cage activity were allowed in the postoperative 
period. Mice were closely monitored during the postoperative period for any adverse 
reactions. At tissue harvest, the left plantaris tendons were collected for gene 
expression analysis, while the right plantaris tendons were used for histological 
examination. After the tendons were removed, mice were euthanized by cervical 
dislocation and induction of bilateral pneumothorax. Plantaris tendons from additional 
non-overloaded mice were obtained as described above for gene expression analysis. 
 Inhibition of PDGFR Signaling. Within each group of mice, half of the mice were 
treated with vehicle or CP-673,451 (Biorbyt, Cambridge, UK), a specific inhibitor of 
PDGFRα and PDGFRβ (6, 38). CP-673,451 inhibits both PDGFRα and PDGFRβ 
kinases with greater than 450-fold selectivity compared to other structurally related 
kinases, including vascular endothelial growth factor receptor (VEGFR), fibroblast 
growth factor receptor (FGFR), epidermal growth factor receptor (EGFR) and insulin-like 
growth factor 1 receptor (IGF1R) (38). CP-673,451 was dissolved first in 2 parts 
dimethyl sulfoxide and then in 8 parts phosphate-buffered saline. CP-673,451 was 
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administered by intraperitoneal injection at 15 mg/kg twice daily, with a total daily dose 
of 30 mg/kg, starting the day prior to synergist ablation and continued each day until 
tissue harvest. This dose has previously been shown to be effective at inhibiting 
PDGFR phosphorylation in mice in vivo (38, 46).  
 Histology. Histological examination of the tendon tissue was performed as 
described previously (43, 46). Plantaris tendons were placed in 30% sucrose solution 
for one hour, snap frozen in Tissue-Tek OCT Compound (Sakura Finetek, Torrance, 
CA, USA) and stored at -80°C until use. Tendons were sectioned at a thickness of 10 
µm in a cryostat and stained with hematoxylin and eosin (H&E) to determine tendon 
CSA and cell density. For immunohistochemistry, tendon sections were fixed in 4% 
paraformaldehyde, permeabilized with 0.2% Triton X-100, and blocked with 5% goat 
serum. To identify cell types in non-overloaded and overloaded tendons, slides from 
PDGFRαEGFP/+ mice were incubated with rabbit anti-PDGFRβ (1:100; sc-339, Santa 
Cruz Biotechnology, Santa Cruz, CA, USA) primary antibodies. To identify proliferating 
cells in overloaded tendons treated with vehicle or PDGFR inhibitor, slides from WT 
mice subjected to synergist ablation were incubated with rabbit anti-Ki67 (1:100; 
ab16667, Abcam, Cambridge, MA, USA) primary antibodies. Primary rabbit antibodies 
against p-PDGFRαY849/PDGFRβY857 (1:100; #3170, Cell Signaling Technology, 
Danvers, MA, USA) were also used on slides from C57BL/6 mice to determine 
differences in the level of PDGFR phosphorylation in response to vehicle or PDGFR 
inhibitor treatment. The tendon ECM was identified with wheat germ agglutinin (WGA) 
lectin conjugated to Alexa Fluor 488 (AF488) (1:200; W11261, Thermo Fisher Scientific, 
Carlsbad, CA, USA). Secondary antibodies conjugated to AF555 (1:300; A-21429, 
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Thermo Fisher Scientific) were used to detect primary antibodies. Nuclei were 
counterstained with DAPI (1:500; D9542, Sigma Aldrich, St. Louis, MO, USA). High-
resolution digital images were captured with an Olympus BX-51 microscope and 
camera (Olympus, Center Valley, PA, USA) for the H&E and Ki67 slides, while a Nikon 
A1 confocal laser microscrope (Nikon Instruments, Tokyo, JP) was used for the PDGFR 
slides. Quantification was performed by study personnel in a blinded fashion using 
ImageJ software (NIH, Bethesda, MD, USA). 
 Cell Culture. Fibroblasts were isolated from the tail tendons of mice as described 
previously (17). Tail tendons are useful for obtaining a large number of early passage 
cells, and they arise from the same population of somitic progenitor cells as limb 
tendons during development (31). Briefly, mice were anesthetized as described above, 
the tail was removed, and animals were euthanized by cervical dislocation. Fascicles 
were isolated from tail tendons, and then were finely minced and placed in low-glucose 
Dulbecco’s Modified Eagle Medium (DMEM; Gibco, Carlsbad, CA, USA) containing 
0.2% type II collagenase (Gibco) for 1 hour at 37°C with constant agitation. An equal 
volume of growth medium (GM) that consists of low-glucose DMEM with 10% fetal 
bovine serum (FBS; Gibco) and 1% antibiotic-antimycotic (Gibco) was added to the 
digested tissue to inactivate the collagenase. Cells were pelleted by centrifugation at 
300g for 10 minutes, resuspended in GM and plated on 100-mm type I collagen-coated 
dishes (Corning, Corning, NY, USA). All cells were maintained in humidified incubators 
at 37°C and 5% CO2. Passage 2-3 cells were used in all experiments. To block PDGFR 
signaling, cells were incubated with 1 μM CP-673,451, as described above. 
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Migration Assay. Type I collagen was acid-extracted from cadaver rat tail 
tendons as described by Hotary et al (16). Briefly, tendons were excised and placed in 
0.2% acetic acid for 5 days at 4°C. The collagen solution was then centrifuged at 
24,000g for 30 minutes, and the supernatant was collected, lyophilized and dissolved 
again in 0.2% acetic acid to a final concentration of 2.7 mg/ml. Collagen hydrogels were 
prepared in the upper chambers of Transwell dishes (12-mm diameter, 3-µm pore size; 
Corning) by combining the collagen solution with 10× Minimum Essential Medium 
(MEM, Thermo Fisher Scientific) and 0.34 N NaOH in an 8:1:1 ratio. After 45 minutes at 
37°C, the gelling process was complete and 1 × 105 tendon fibroblasts were seeded on 
top of the collagen hydrogels. PDGF-BB (20 ng/ml; R&D Systems, Minneapolis, MN, 
USA) was added to the lower chambers to initiate migration of the cells into the collagen 
hydrogels. Where indicated, media was supplemented with TGF-β1 (10 ng/ml; 
PeproTech, Rocky Hill, NJ, USA), the synthetic broad spectrum MMP inhibitor BB-94 (5 
µM; Tocris Bioscience, Bristol, UK), the mitogen-activated protein kinase kinases 1 and 
2 (MEK1/2) inhibitor PD98059 (50 µM; InvivoGen, San Diego, CA, USA) or the PI3K 
inhibitor wortmannin (10 µM; InvivoGen). All media, including growth factors and 
inhibitors, were replaced every 2 days. Migratory activity was monitored by phase-
contrast microscopy, and the cells were allowed to migrate for 6 days. The number of 
migrating cells and the maximum distance migrated were quantified in 5 randomly 
selected fields of a single experiment from 3 or more independent experiments 
performed.  
Proliferation Assay. Uptake of bromodeoxyuridine (BrdU) by proliferating tendon 
fibroblasts was measured as described previously (28). Tendon fibroblasts were 
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incubated overnight with or without 20 ng/ml of PDGF-BB in media containing 0.5% 
FBS. After overnight incubation, fresh media was added along with 20 µM of BrdU 
(Sigma Aldrich) for 1 hour. Cells were then rinsed with phosphate-buffered saline, fixed 
in ice-cold methanol and permeabilized with 0.5% Triton X-100. The BrdU epitope was 
exposed by denaturing DNA with 2 M HCl. BrdU was visualized with an anti-BrdU 
antibody (1:50; G3G4, Developmental Studies Hybridoma Bank, Iowa City, Iowa, USA) 
and a secondary antibody conjugated to AF555 (1:200; A-21127, Thermo Fisher 
Scientific). Nuclei were counterstained with DAPI (1:500; D9542, Sigma Aldrich) to 
determine total cell number. The number of proliferating cells were quantified in 5 
randomly selected fields of a single experiment from 6 independent experiments 
performed. 
 Quantitative RT-PCR. Gene expression analysis was performed as described 
previously (17, 47). Plantaris tendons were homogenized in QIAzol (Qiagen, Valencia, 
CA, USA) and RNA was purified using a miRNeasy Micro Kit (Qiagen) supplemented 
with DNase I (Qiagen). RNA was reverse transcribed into cDNA with iScript Reverse 
Transcription Supermix (Bio-Rad, Hercules, CA, USA). Amplification of cDNA was 
performed in a CFX96 real-time thermal cycler (Bio-Rad) using iTaq Universal SYBR 
Green Supermix (Bio-Rad). Target gene expression was normalized to the stable 
housekeeping gene peptidylprolyl isomerase D (PPID), and further normalized to 
tendons that were not subjected to synergist ablation using the 2-ΔΔCt method. PPID was 
selected as a housekeeping gene from microarray data and validated with qPCR. For 
cell culture experiments, relative copy number was calculated using the linear 
regression of efficiency method (40). Primer sequences are provided in Table S1. 
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 Microarray. Microarray measurements were performed by the University of 
Michigan DNA Sequencing Core as described previously (17, 46). Equal amounts of 
RNA isolated from four individual tendons were pooled into a single sample for 
microarray analysis, and two pooled samples from each group were analyzed. RNA was 
pooled because gene expression from a pooled sample is similar to the average of the 
individual samples composing the pooled sample (3, 21). Biotinylated cDNA was 
prepared using the GeneChip WT PLUS Reagent Kit (Affymetrix, Santa Clara, CA, 
USA) and hybridized to Mouse Gene 2.1 ST Array Strips (Affymetrix). Raw microarray 
data were loaded into ArrayStar version 12.1 (DNASTAR, Madison, WI, USA) to 
calculate fold changes in gene expression. The microarray dataset was made available 
through the NIH Gene Expression Omnibus database (accession number GSE95794). 
 siRNA Transfection. Predesigned fluorescent-labeled siRNAs directed against 
mouse MT1-MMP (NM_008608; SI02733822, Qiagen) were transfected into tendon 
fibroblasts using Lipofectamine RNAiMAX (Thermo Fisher Scientific) at a final 
concentration of 10 nM. AllStars Negative Control siRNA (Qiagen) was used as a 
negative control. Fluorescence microscopy demonstrated that ~99% of the cells were 
transfected at 24 hours. Efficiency of MT1-MMP mRNA knockdown was determined 48 
hours after transfection by qPCR. 
Immunoblots. Immunoblots were performed as described (17, 46). Whole 
tendons and cell pellets were homogenized in ice cold RIPA buffer (Sigma Aldrich) 
supplemented with 1% protease and phosphatase inhibitor cocktail (Thermo Fisher 
Scientific). Protein homogenates were diluted in Laemmli’s sample buffer, boiled for two 
minutes and 20 µg of protein was separated on either 6% or 12% SDS-PAGE gels 
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depending on the protein of interest. Proteins were transferred to 0.45-µm nitrocellulose 
membranes (Bio-Rad) using the Trans-Blot SD semi-dry transfer apparatus (Bio-Rad), 
blocked with 5% non-fat powdered milk in TBST solution and incubated with primary 
rabbit antibodies (1:1000; Cell Signaling Technology) against p-
PDGFRαY849/PDGFRβY857 (#3170), PDGFRα (#3174), PDGFRβ (#3169), p-
ERK1/2T202/Y204 (#4370), ERK1/2 (#4695), p-AktT308 (#13038), Akt (#4691), p-
p70S6KT389 (#9234) and p70S6K (#2708), primary rabbit antibodies (1:1000; Abcam) 
against MT1-MMP (ab51074) or primary rabbit antibodies (1:1000; Santa Cruz 
Biotechnology) against procollagen type I (Pro-Col1a1; sc-30136). β-tubulin (ab6046, 
Abcam) or Coomassie staining were used to determine equal protein loading. Following 
primary antibody incubation, membranes were rinsed and incubated with HRP-
conjugated goat anti-rabbit secondary antibodies (1:10,000; ab97051, Abcam). Proteins 
were detected using enhanced chemiluminescent reagents (Bio-Rad) and visualized 
using a digital chemiluminescent documentation system (Bio-Rad). 
Cell Surface Biotinylation. Cell surface proteins from tendon fibroblasts were 
biotinylated and purified using the Cell Surface Protein Isolation Kit (Thermo Fisher 
Scientific). Briefly, cells in monolayer were washed with ice-cold phosphate-buffered 
saline and incubated with 0.25 mg/ml of Sulfo-NHS-SS-Biotin for 30 minutes at 4°C with 
constant agitation. Adherent cells were then lysed and the biotinylated proteins were 
affinity-purified using streptavidin agarose beads. Biotinylated proteins were analyzed 
by immunoblotting with anti-MT1-MMP (ab51074, Abcam) antibodies. GAPDH (MA5-
15738, Thermo Fisher Scientific) from the whole cell lysate and Coomassie staining 
were used to determine equal protein loading. 
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Statistics. Results are presented as mean±SD. Prism version 7.0 (GraphPad 
Software, La Jolla, CA, USA) was used to conduct statistical analyses. A two-way 
ANOVA (α=0.05) followed by Tukey’s post hoc sorting evaluated the interaction 
between time after synergist ablation and PDGFR inhibitor treatment. For cell culture 
experiments, differences between groups were tested with an unpaired Student’s t-test 
or a one-way ANOVA followed by Tukey’s post hoc sorting where indicated with α=0.05. 
 
Results 
PDGFRα and PDGFRβ are expressed in tendon. We first sought to determine 
which cells in tendon express the PDGFRs. Tendon fibroblasts in non-overloaded 
tendons express both PDGFRα and PDGFRβ (PDGFRα+/PDGFRβ+) (Figure 3.1B). This 
was also observed within regions of neotendon tissue in the 3- and 10-day overloaded 
tendons (Figure 3.1C-D). Very few cells were found that express PDGFRα alone 
(PDGFRα+/PDGFRβ-), while a small population of cells near blood vessels in the 
epitenon of non-overloaded tendons and in the neotendon of overloaded tendons were 
discovered to express PDGFRβ alone (PDGFRα-/PDGFRβ+). In vitro, tendon fibroblasts 
expressed both PDGFR subtypes (PDGFRα+/PDGFRβ+) (Figure 3.1E). 
PDGFR inhibition prevents growth of adult tendon tissue after mechanical 
overload. To determine the functional importance of PDGFR signaling during postnatal 
tendon growth, pharmacological blockade of both PDGFR subtypes was performed in 
adult wild-type C57BL/6 mice followed by mechanical overload using the hindlimb 
synergist ablation model. To verify the ability of CP-673,451 to inhibit phosphorylation of 
both PDGFR subtypes in tendon fibroblasts, cells isolated from tail tendons of wild-type 
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C57BL/6 mice were growth arrested in serum-free media and incubated alone or with 
PDGF-BB for 30 minutes. Under these conditions, tendon fibroblasts responded to 
PDGF-BB stimulation by activating PDGFRα and PDGFRβ (Figure 3.2A). In contrast, 
tendon fibroblasts pretreated with 1 µM CP-673,451 displayed no activation of the 
PDGFR subtypes upon stimulation with PDGF-BB (Figure 3.2A). Next, we collected 
whole tendon lysates from 3-day overloaded mice that had been treated with vehicle or 
CP-673,451 to determine the ability of CP-673,451 to inhibit phosphorylation of both 
PDGFR subytpes in vivo. Mice treated with CP-673,451 demonstrated reduced levels of 
p-PDGFRαY849/PDGFRβY857 compared to vehicle-treated controls (Figure 3.2B). 
Additionally, mice treated with the PDGFR inhibitor displayed significant attenuation of 
major downstream signaling cascades as evidenced by reduced levels of p-AktT308 and 
p-ERK1/2T202/Y204 compared to vehicle-treated controls (Figure 3.2B). These findings 
were also supported by immunofluorescence of tendon sections taken 3 days after 
mechanical overload, which demonstrated fewer cells expressing p-
PDGFRαY849/PDGFRβY857 in response to PDGFR inhibitor treatment (Figure 3.2C). 
Mechanical overload of the plantaris tendons resulted in outward growth of a 
neotendon matrix from the most superficial layers of the original tendon (Figure 3.3A). 
Overall, PDGFR inhibition did not impact the general morphological features of the 
plantaris tendons, but noticeable differences in tendon CSA and cell density were 
observed (Figure 3.3B-G). For the original tendon, the CSA of the 10-day vehicle group 
was slightly larger than both the 3-day vehicle and PDGFR inhibitor groups, but 
otherwise CSA of the original tendon did not change in response to time after overload 
or treatment with PDGFR inhibitor (Figure 3.3B). In contrast, the CSA of the neotendon 
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in the 3- and 10-day PDGFR inhibitor groups was 50% and 59% smaller compared to 
their respective vehicle-treated controls (Figure 3.3C). Changes in total tendon CSA 
generally followed the same trends observed in the neotendon data (Figure 3.3D). For 
the original tendon, the cell density of all groups was similar and did not change in 
response to time after overload or treatment with PDGFR inhibitor (Figure 3.3E). 
However, the cell density of the neotendon in the 10-day vehicle group was 60% higher 
compared to both the 3-day vehicle and PDGFR inhibitor groups, and this increase was 
not observed in response to PDGFR inhibition (Figure 3.3F). Similar to the total tendon 
CSA results, changes in total tendon cell density generally followed the same trends 
observed in the neotendon data (Figure 3.3G). 
Previous reports have demonstrated PDGF-BB-dependent proliferation of tendon 
fibroblasts in vitro (53), and while we also observed that tendon fibroblasts stimulated 
with PDGF-BB proliferate at higher rates compared to cells cultured in low-serum media 
(Figure 3.4), we were mainly interested in determining if global inhibition of PDGFR 
signaling during mechanical overload prevents proliferation of tendon fibroblasts. In 
general, mechanical overload results in greater abundance of Ki67-expressing cells in 
the neotendon compared to the original tendon of all groups (Figure 3.5A). For the 
original tendon, the number of proliferating cells in all groups was similar and did not 
change in response to time after overload or treatment with PDGFR inhibitor (Figure 
3.5B). In contrast, the number of proliferating cells in the neotendon of the 3- and 10-
day PDGFR inhibitor groups was 55% and 76% less compared to their respective 
vehicle-treated controls (Figure 3.5C). Changes in the number of proliferating cells in 
the total tendon generally followed the same trends observed in the neotendon data 
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(Figure 3.5D). Taken together, these results indicate that PDGFR inhibition suppresses 
the normal growth of tendon tissue after mechanical overload, and this is partly 
explained by defects in cell proliferation. 
Transcriptomic analysis of PDGFR-inhibited tendons demonstrates defects in 
angiogenesis, ECM synthesis and remodeling, expression of MMPs and tissue 
inhibitors of metalloproteinases (TIMPs), cell specification and proliferation, and cell 
migration. Since inhibition of PDGFR signaling resulted in a tendon growth phenotype, 
we sought to further explore the mechanisms behind this response by conducting 
transcriptional profiling. Using a minimum and maximum fold change of 1.5, microarray 
experiments identified that approximately 10% of the genome was differentially 
expressed in both the 3- and 10-day groups, with slight differences between vehicle- 
and PDGFR-treated animals at each time point (Figure 3.6A-B). By 10 days, the overall 
number of differentially expressed transcripts was less than 3 days, although the 
number of unique transcripts expressed in both PDGFR inhibitor groups was similar at 
each time point (Figure 3.6B). Gene ontology (GO) analysis demonstrated that PDGFR 
signaling governs multiple processes critical to tendon fibroblast function, with the 
greatest enrichment observed in biological adhesion and locomotion (Figure 3.6C). 
Based on the results of the microarray experiments and GO analysis, we 
followed up on genes of interest with qPCR. For markers of angiogenesis, multiple 
genes demonstrated reduced expression in the 10-day PDGFR inhibitor compared to 
vehicle-treated controls, including platelet/endothelial cell adhesion molecule 1 
(PECAM1), also known as CD31, which is a membrane glycoprotein involved in cell 
adhesion of endothelial cells, and CD146, another adhesion molecule that is highly 
	 74 
expressed by pericytes (Figure 3.7A). CD248, which is a C-type lectin domain protein 
important for angiogenesis, was did not increase at 3 and 10 days in response to 
PDGFR inhibition. Interestingly, thrombospondin 1 (TSP1), which is a secreted 
glycoprotein that inhibits angiogenesis through direct effects on endothelial cell 
proliferation and migration, also did not increase at 10 days in the PDGFR inhibitor 
group compared to vehicle-treated controls, while slight changes in the expression of 
the angiogenic growth factor vascular endothelial growth factor A (VEGFA) were noted 
as a result of time after overload. In addition to the changes observed in markers of 
angiogenesis, numerous ECM synthesis and remodeling genes were also affected by 
PDGFR inhibition (Figure 3.7B). Expression of all the fibrillar types I, III and V collagens 
as well as the network types IV and VI collagens did not increase at 10 days in 
response to PDGFR inhibition, while no differences in expression for any of the 
collagens were observed between the 3-day vehicle and PDGFR inhibitor groups. Given 
that type I collagen is the main structural protein of tendon, we sought to determine if 
the reduction in type I collagen transcripts at the whole tissue level was a direct effect of 
PDGFR inhibition on tendon fibroblasts or an indirect effect related to a decrease in cell 
number. Tendon fibroblasts were isolated from tail tendons of wild-type C57BL/6 mice 
and incubated alone or with PDGF-BB for 24 hours in serum-free conditions. PDGF-BB 
stimulation had no significant effect on Col1a1 and Col1a2 transcript levels or Pro-
Col1a1 protein expression (Figure 3.8A-C). These results indicate that PDGF-BB does 
not regulate expression of type I collagen at the mRNA and protein levels in tendon 
fibroblasts, and hence the reduction in type I collagen transcripts at the whole tissue 
level is likely an indirect effect related to a decrease in cell number. 
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Accompanying the changes observed in ECM synthesis and remodeling genes, 
PDGFR inhibition also resulted in marked changes in the expression of MMPs and their 
endogenous TIMPs (Figure 3.7C). For the gelatinases, MMP2 expression was 59% 
lower at 10 days in the PDGFR inhibitor group compared to vehicle-treated controls, 
while MMP9 was 83% higher at 3 days in response to PDGFR inhibition. Similar to 
MMP9, the collagenase MMP8 was 89% higher at 3 days in response to PDGFR 
inhibition, whereas no differences in the expression of collagenase MMP13 were 
demonstrated in response to time after overload or treatment with PDGFR inhibitor. 
MT1-MMP, also known as MMP14, was dramatically upregulated by greater than 5- and 
46-fold at 3 and 10 days after mechanical overload, respectively, and treatment with the 
PDGFR inhibitor prevented the increase in transcript levels at 10 days compared to 
vehicle-treated controls. Compared to the 3-day time point, TIMP1 transcript levels were 
lower in both 10-day groups, while TIMP2 transcript levels did not increase at 10 days in 
response to PDGFR inhibition. 
Transcription factors that play crucial roles in different stages of tendon 
development were upregulated after mechanical overload (Figure 3.7D). The basic 
helix-loop-helix transcription factor scleraxis (Scx) was upregulated greater than 2-fold 
at both 3 and 10 days and was not affected by PDGFR inhibitor treatment. After an 
initial downregulation of the atypical homeodomain transcription factor mohawk (Mkx) 
and the type II transmembrane glycoprotein tenomodulin (Tnmd) at 3 days, their 
transcript levels increased by 10 days compared to non-overloaded controls in the 
absence of PDGFR inhibition. The zinc finger transcription factors early growth 
response 1 and 2 (Egr1 and Egr2) did not increase at 10 days in response to PDGFR 
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inhibition, while Egr2 expression was also 71% lower at 3 days in the PDGFR inhibitor 
group compared to vehicle-treated controls. The changes in Ki67 signal present on 
immunofluorescence (Figure 3.5A) were accompanied by quantitative changes in gene 
expression. Marker of proliferation Ki67 (Mki67) transcript levels did not increase at 3 
and 10 days in response to PDGFR inhibition. In addition to the changes observed in 
cell specification and proliferation genes, numerous cell migration genes were also 
affected by PDGFR inhibition (Figure 3.7E). Angiomotin-like protein 2 (AmotL2), which 
is a membrane-associated scaffold protein that localizes to lamellipodia during cell 
migration, and myosin light chain 9 (Myl9), which regulates contractility and cytoskeletal 
tension during cell migration, both did not increase at 10 days in response to PDGFR 
inhibition. The cytokinetic scaffold protein anillin (Anln), which binds F-actin and can 
recruit Rho GTPases to the leading edge of the cell membrane during cell migration, did 
not increase at 3 days in response to PDGFR inhibition. Other actin-binding proteins 
that help reorganize the actin cytoskeleton during cell migration include transgelin 
(Tagln), filamin A (Flna) and diaphanous related formin 3 (Diaph3), and whereas the 
expression of all of these genes increased after mechanical overload, none of them 
were affected by PDGFR inhibitor treatment. In contrast, ankyrin repeat domain 1 
(Ankrd1), which is a transcriptional repressor of MMP13, increased by greater than 3-
fold in the 3-day PDGFR inhibitor group compared to vehicle-treated controls. The 
matricellular proteins cysteine-rich angiogenic inducer 61 (Cyr61) and connective tissue 
growth factor (CTGF) are key mediators of cell migration through their interaction with 
cell surface integrins, and while Cyr61 was not affected by PDGFR inhibition, CTGF 
expression was 65% lower at 10 days in the PDGFR inhibitor group compared to 
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vehicle-treated controls. Overall, these results indicate that PDGFR inhibition exerts 
profound effects on the transcriptome of plantaris tendons during mechanical overload, 
and influences multiple processes critical to proper tendon growth, including 
angiogenesis, ECM synthesis and remodeling, proliferation and cell migration.  
MT1-MMP is an essential proteinase for tendon fibroblast migration through 
tendon ECM. Based on the gene expression data, we identified MT1-MMP as the most 
highly upregulated MMP after mechanical overload whose expression at 10 days was 
attenuated in response to PDGFR inhibition (Figure 3.7C). Previous reports have 
recognized MT1-MMP as a key effector of migratory behavior in many different cell 
types due to its pericellular collagenolytic activity (8, 41), but its role in tendon fibroblast 
migration has remained largely unexplored. Using cross-linked type I collagen hydrogels 
that closely recapitulate the tendon ECM environment in vivo (16, 41), tendon 
fibroblasts were cultured on top of the hydrogels and migration was initiated by a 
chemotactic gradient of PDGF-BB (Figure 3.9A). Over a 6-day culture period, tendon 
fibroblasts migrated into the hydrogel and the number of migrating cells as well as the 
maximum distance migrated were assessed by light microscopy (Figure 3.9B-D). In the 
absence of PDGF-BB, or in response to transforming growth factor beta 1 (TFG-β1) 
treatment, which has been shown to stimulate tendon fibroblast migration in explant 
cultures of rat patellar tendon (7), tendon fibroblasts did not migrate into the hydrogel. 
Furthermore, the migratory activity of tendon fibroblasts was completely inhibited in the 
presence of BB-94, a synthetic broad spectrum MMP inhibitor, which indicates that the 
ability of tendon fibroblasts to migrate through the hydrogel is a proteinase-dependent 
process. To determine the role of MT1-MMP in tendon fibroblast migration, siRNAs 
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were directed against MT1-MMP and their impact on the migratory activity of tendon 
fibroblasts was assessed. Silencing efficiency of the MT1-MMP siRNAs was confirmed 
without detectable off-target effects on other MMP transcripts (Figure 3.8D-E). Over a 6-
day culture period, the chemotactic response of MT1-MMP-silenced tendon fibroblasts 
to PDGF-BB stimulation was completely abolished compared to scrambled siRNA 
controls (Figure 3.10A-C). Taken together, these results indicate that MT1-MMP is 
required for tendon fibroblast migration through cross-linked type I collagen hydrogels 
that closely recapitulate tendon ECM environment in vivo. 
PDGF-BB increases MT1-MMP expression in tendon fibroblasts via PI3K/Akt-
mediated translational and ERK1/2-mediated post-translational mechanisms. Activation 
of the PI3K/Akt and ERK1/2 pathways has been previously linked to PDGF-BB-
dependent migratory activities in other cell types (48). To determine the integrity of 
these downstream signaling cascades in tendon fibroblasts, cells isolated from tail 
tendons of wild-type C57BL/6 mice were growth arrested in serum-free media and 
incubated alone or with PDGF-BB for 60 minutes. Under these conditions, tendon 
fibroblasts responded to PDGF-BB stimulation by activating both Akt and ERK1/2 
(Figure 3.11A). Both maximum Akt and ERK1/2 activation occurred at 5 minutes, and 
while p-AktT308 levels then steadily declined, p-ERK1/2T202/Y204 levels were more 
transient and returned to near baseline levels by 60 minutes post-stimulation. 
Consistent with Akt activation, p-p70S6KT389 levels began to rise within 5 minutes and 
peaked at 15 minutes with sustained activation noted thereafter. To gain insight into the 
regulation of tendon fibroblast migration by the PI3K/Akt and ERK1/2 pathways, cells 
were cultured on top of collagen hydrogels and migration was assessed in the presence 
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of either the PI3K inhibitor wortmannin or the MEK1/2 inhibitor PD98059. Over a 6-day 
culture period, the migratory activity of tendon fibroblasts in the presence of either 
inhibitor was significantly inhibited as assessed by light microscopy (Figure 3.11B-D). 
Next, we sought to determine the molecular connection between MT1-MMP expression 
and both the PI3K/Akt and ERK1/2 pathways in tendon fibroblasts. Cells isolated from 
tail tendons of wild-type C57BL/6 mice were incubated alone or with PDGF-BB for 24 
hours in low-serum conditions. PDGF-BB stimulation had no significant effect on MT1-
MMP transcript levels (Figure 3.12A). On immunoblots, three distinct bands were 
visualized for the MT1-MMP protein at 63, 60 and 45 kD, which correspond to the pro-
form, the active form and the processed form of the enzyme (Figure 3.12B). In response 
to PDGF-BB stimulation, Akt and ERK1/2 activation were accompanied by a 1.4-fold 
increase in total MT1-MMP protein expression, which includes all forms of the enzyme 
(Figure 3.12C-E). However, in the presence of wortmannin, activation of Akt was 
blocked, but total MT1-MMP protein expression did not increase. In the presence of 
PD98059, while the activation of ERK1/2 was blocked, total MT1-MMP protein 
expression increased similar to PDGF-BB stimulation in the absence of either inhibitor. 
Interestingly, the increase in total MT1-MMP protein expression in the PD98059 group 
was accounted for by an increase in the pro-form of the enzyme, while the active and 
processed forms did not increase (Figure 3.12F-H). Thus, the ratio between the active 
and pro-forms of MT1-MMP was 47% lower in the PD98059 group compared to all other 
groups (Figure 3.12I). Given that the active form of MT1-MMP can be found at the cell 
membrane where it is responsible for extracellular proteolysis, we next sought to 
determine cell surface levels of the MT1-MMP protein in response to PDGF-BB 
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treatment. Cells isolated from tail tendons of wild-type C57BL/6 mice were incubated 
alone or with PDGF-BB for 24 hours in low-serum conditions, after which cell surface 
biotinylation and immunoblotting were performed. Similar to the findings from whole cell 
lysates, an increase in cell surface MT1-MMP was demonstrated with PDGF-BB 
stimulation, while both wortmannin and PD98059 blocked the increase of MT1-MMP at 
the cell surface (Figure 3.13A-C). Take together, these results indicate that PDGF-BB-
dependent MT1-MMP expression in tendon fibroblasts is regulated by PI3K/Akt-
mediated translational and ERK1/2-mediated post-translational mechanisms (Figure 
3.13D). 
  
Discussion 
The ability of tendon tissue to transmit force generated by muscular contraction is 
critical to the overall health of the musculoskeletal system. In response to changes in 
mechanical load, tendon actively remodels its ECM to meet the new demands placed 
on it, which is typically accompanied by increases in tendon CSA, cell density and type I 
collagen content (9, 27). While PDGFR signaling is known to regulate fundamental 
biological activities of many cells that compose musculoskeletal tissues, its role in 
postnatal tendon growth and remodeling has remained largely unexplored. In the 
current study, we report that tendon fibroblasts express both PDGFRs, PDGFRα and 
PDGFRβ, and that inhibition of signaling through these receptors during mechanical 
overload suppresses the normal growth of tendon tissue due to defects in cell 
proliferation and migration. Furthermore, we identify MT1-MMP as an essential 
proteinase for tendon fibroblast migration through tendon ECM, and demonstrate that 
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MT1-MMP translation is regulated by PI3K/Akt, while ERK1/2 controls post-translational 
trafficking of MT1-MMP within tendon fibroblasts. These findings highlight the crucial 
role that PDGFR signaling plays in the adaptation of adult tendons to mechanical 
growth stimuli, and earmark MT1-MMP as a potential therapeutic target in the treatment 
of tendon injuries and diseases. 
The growth of new tendon tissue during mechanical loading is a complex process 
that requires a coordinated effort between tendon fibroblasts and their local ECM 
environment. Tendon fibroblasts constantly sense and respond to biomechanical and 
biochemical cues in the tendon ECM, and an increase in mechanical load placed on the 
tendon is often a signal for growth. In response to a mechanical growth stimulus, tendon 
fibroblasts begin to proliferate, migrate into areas of newly formed tendon tissue and 
synthesize new matrix proteins. Each of these elements – proliferation, migration and 
ECM synthesis and remodeling – are required for proper tendon growth, and a defect in 
any one of them can result in impairment of this process. In the current study, we 
demonstrated that growth of the plantaris tendon from mechanical overload was 
prevented by PDGFR inhibition, largely due to defects in cell proliferation and migration. 
Our findings of smaller tendons with fewer proliferating cells in PDGFR inhibitor-treated 
animals is supported by PDGF-BB-dependent increases in proliferation and migration of 
tendon fibroblasts in our tissue culture experiments. Additionally, differences in tendon 
morphology as a result of PDGFR inhibition were accompanied by quantitative changes 
in the expression of cell proliferation and migration genes. Mki67 expression did not 
increase at 3 and 10 days in response to PDGFR inhibition, and various genes involved 
in actin reorganization and cytoskeletal tension, including AmotL2, Myl9 and Anln, also 
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did not increase in the PDGFR inhibitor-treated animals during mechanical overload. 
Interestingly, Ankrd1 was significantly upregulated in response to PDGFR inhibition, 
whereas transcript levels of the matricellular protein CTGF did not increase. CTGF has 
been shown to enhance cell migration by upregulating MMP13 expression, while 
Ankrd1 is a known transcriptional repressor of MMP13 (50). Even though MMP13 
expression was not directly affected by PDGFR inhibition, mechanical overload resulted 
in MMP13 upregulation compared to non-overloaded controls. As tendons grow in 
response to mechanical loading, they require ingrowth of new vasculature to keep up 
with the metabolic demands of the tissue. Even though we did not detect any gross 
morphological changes in capillary structure, the transcript levels of multiple 
angiogenesis genes failed to increase due to PDGFR inhibition, including the 
endothelial cell adhesion molecules PECAM1 and CD248, as well as the pericyte 
marker CD146, which represents a potential source of pluripotent stem cells during 
tendon regeneration (19, 24). Finally, the expression of TSP1, an endogenous inhibitor 
of angiogenesis, did not increase in the overloaded PDGFR inhibitor-treated mice, and 
TSP1 has been shown to activate latent transforming growth factor beta (TGF-β) to 
enhance ECM synthesis and remodeling (49). 
 Mechanical overload resulted in upregulation of many mesenchymal tendon 
fibroblast markers, including Scx, Tnmd, Mkx, Egr1 and Egr2, which is consistent with 
previous studies of tendon growth (27, 43). PDGF-BB is known to regulate Egr1 
transcript levels, and both Egr1 and Egr2 expression in PDGFR inhibitor-treated mice 
were blocked during mechanical overload compared to vehicle-treated controls (30). 
Many of these transcription factors are known to regulate type I collagen expression by 
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tendon fibroblasts (26), and PDGFR inhibition in the current study produced significant 
changes in ECM synthesis and remodeling genes. For all of the fibrillar (I, III and V) and 
network (IV and VI) collagens, increases in their transcript levels at 10 days were 
blocked in the PDGFR inhibitor-treated mice compared to vehicle-treated controls. 
However, we looked at type I collagen expression more closely by tendon fibroblasts in 
vitro, since it is the predominant structural protein in tendon, and found that tendon 
fibroblasts treated with PDGF-BB demonstrated no significant increases in both Col1a1 
and Col1a2 transcript levels or Pro-Col1a1 protein levels. These results indicate that 
type I collagen expression by tendon fibroblasts is not transcriptionally or translationally 
regulated by PDGF-BB, and further suggests that the decrease in type I collagen 
expression observed at the whole tissue level was likely an indirect effect from reduced 
cell number, or it was mediated through an intermediary signaling molecule or growth 
factor other than PDGF-BB. Along these lines, previous studies have demonstrated 
increased type I collagen synthesis in canine tendon fibroblasts and explant cultures of 
rabbit tendons as a result of PDGF-BB stimulation, but this was measured as 3H-proline 
incorporation without measuring transcript or protein levels (53, 56). Finally, mechanical 
overload resulted in upregulation of multiple MMPs, including MMP2, MMP8, MMP9, 
MMP13 and MT1-MMP, as well as their endogenous inhibitors TIMP1 and TIMP2. 
These findings are consistent with previous models of tendon growth (27, 43), and while 
PDGFR inhibition demonstrated mixed effects on the expression of the various 
metalloproteinases, these results are representative of the dramatic remodeling that 
takes place in the tendon ECM during mechanical overload. 
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In mechanically-loaded tendons, adaptation of the tendon ECM is mediated by 
fibroblasts migrating into tendon fascicles and synthesizing new matrix proteins (27). 
The tendon ECM is highly enriched in type I collagen, a protein whose triple helical 
structure makes it resistant to most forms of proteolytic attack (33). For tendon fibroblast 
migration to occur, type I collagen and other matrix proteins need to be cleaved in order 
to create space for the cells to move. In the current study, we identify MT1-MMP as the 
essential proteinase for tendon fibroblast migration through cross-linked type I collagen 
hydrogels that closely recapitulate the tendon ECM environment in vivo. While secreted 
MMPs play an important role in tissue remodeling, their site of action is distant to their 
point of secretion, which impairs their ability to regulate cell migration (41, 42). In 
contrast, MT-MMPs are anchored to the cell membrane, which confines their type I 
collagenolytic activity to the pericellular microenvironment, and supports their role as the 
primary effectors of cellular movement (16, 41). Our findings are consistent with 
previous studies that have shown cells deficient in MT1-MMP lose their ability to 
penetrate type I collagen barriers (18, 41, 45). Knockout mouse models of single MMPs 
have also been generated to test their importance in vivo, with most mice being viable 
and fertile with very subtle developmental defects, except for mice lacking MT1-MMP 
(32). These mice die within the first few weeks of life and display significant defects in 
fat, bone, cartilage, skeletal muscle and tendon, suggesting that MT1-MMP plays critical 
roles in the growth and development of mesenchymal tissues (15, 51). Additionally, 
mice lacking MT1-MMP in tendon fibroblasts (ScxCre:MT1-MMPf/f) demonstrate a 
severe limb phenotype with marked dorsiflexion of the fore and hind paws (51), 
providing further evidence for the importance of MT1-MMP to overall tendon fibroblast 
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function. Apart from its role in cell migration, MT1-MMP also regulates other key cellular 
processes including proliferation, differentiation and cell survival, by either changing the 
tissue architecture or converting matrix proteins into signaling molecules (18, 32). 
Unlike other musculoskeletal tissues, the molecular signaling pathways that play 
important roles during tendon growth and remodeling in the adult have yet to be 
defined. While the TGF-β superfamily has been shown to be essential for the embryonic 
formation of tendons (11, 37), very few studies have investigated which signaling 
pathways are activated in response to mechanical loading in the adult, and of those 
activated, which are the most important for tendon growth. Popov and colleagues (36) 
demonstrated that mechanically stretching tendon progenitor/stem cells (TPSCs) in 
culture at 8% strain led to activation of ERK1/2 and p38 mitogen-activated protein 
kinase (MAPK), but not Akt. Interestingly, increased MT1-MMP mRNA and protein 
levels were also reported in this model, although the mechanism for this upregulation 
was not determined. Although p38 MAPK is activated in response to mechanical 
stimulation in vitro, inhibition of p38 MAPK had a negligible impact on tendon growth in 
vivo after hindlimb synergist ablation (43). In another study, local insulin-like growth 
factor 1 (IGF-1) expression and ERK1/2 activation was demonstrated in rat 
supraspinatus tendons after 16 weeks of downhill treadmill running (44). However, this 
model caused degenerative changes in the tendon ECM and is more commonly used to 
study tendinopathy than tendon growth. To our knowledge, the current study is the first 
to demonstrate that a particular class of cell surface receptors, namely PDGFRα and 
PDGFRβ, are necessary for tendon growth in vivo. Inhibition of PDGFR signaling in vivo 
blocked phosphorylation of important regulatory sites on Akt and ERK1/2. The T308 site 
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on Akt is phosphorylated by phosphoinositide-dependent kinase 1 (PDK1), while the 
T202/Y204 sites on ERK1/2 are phosphorylated by MEK1/2 (25). One of the main 
downstream targets of Akt is p70 S6 kinase (p70S6K), which upon mechanistic target of 
rapamycin complex 1 (mTORC1)-mediated phosphorylation at the T389 site, it can then 
activate several proteins involved in ribosomal biogenesis and the initiation of mRNA 
translation (57). In contrast, activated ERK1/2 regulates the activities of several 
transcription factors via phosphorylation that lead to the expression of genes involved in 
proliferation, differentiation and cell migration (1). Upon ligand-induced PDGFR 
autophosphorylation, both the PI3K/Akt and ERK1/2 pathways through their respective 
transcriptional targets have been shown to regulate the growth of a wide variety of cell 
types and tissues (1). In the current study, the changes in phosphorylation of Akt and 
ERK1/2 in the PDGFR inhibitor-treated animals correlate with the observed changes in 
tendon growth, and while PDGFR inhibition of perivascular cells may affect 
angiogenesis, most of the observed changes in tendon growth are likely the result of a 
direct effect of the PDGFR inhibitor on tendon fibroblasts, given that they are the 
predominant cell type in adult tendon tissue. 
Activation of the PI3K/Akt and ERK1/2 pathways in mechanically-loaded tendons 
is consistent with PDGF-BB-dependent activation of these pathways in tendon 
fibroblasts in vitro. Both the PI3K/Akt and ERK1/2 pathways mediate tendon fibroblast 
migration through type I collagen hydrogels, and inhibition of these pathways results in 
decreased migratory activity of the cells similar to the MT1-MMP-silenced tendon 
fibroblasts. A previous study by Sun and colleagues (48) demonstrated that rat bone 
marrow-derived mesenchymal stem cells treated with PDGF-BB increased MT1-MMP 
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expression at the mRNA and protein levels, and this response was mediated by the 
PI3K/Akt and ERK1/2 pathways. The results from the current study do not support these 
findings, which suggests that the regulation of MT1-MMP expression in response to 
PDGF-BB stimulation is cell type and tissue dependent. Tendon fibroblasts treated with 
PDGF-BB produce more MT1-MMP protein, but without a change in MT1-MMP 
transcript levels. Treatment with the PI3K inhibitor wortmannin blocked the increase in 
MT1-MMP protein, which indicates that MT1-MMP mRNA translation is regulated by the 
PI3K/Akt pathway in a PDGF-BB-dependent manner. However, treatment with the 
MEK1/2 inhibitor PD98059 did not block the increase in total MT1-MMP protein, but did 
block the increase in the active form of the enzyme. Interestingly, the increase in total 
MT1-MMP protein in the presence of PD98059 is accounted for by an increase in the 
pro-form of the enzyme. To our knowledge, the mechanism by which ERK1/2 inhibition 
leads to more of the pro-form compared to the active form of the enzyme is not known. 
MT1-MMP is synthesized as a zymogen and requires processing in the trans-Golgi 
network (TGN) by furin, a proprotein convertase that recognizes and cleaves a basic 
motif in the prodomain of MT1-MMP, which then exposes the catalytic domain and 
allows the enzyme to become functional (18). Furin is a type I transmembrane protein 
that functions as a serine endoprotease and belongs to the subtilisin-like proprotein 
convertase (SPC) family (52). Interestingly, some members of the SPC family are 
known to be regulated by PDGF-BB (2), and furin expression itself has been shown to 
be regulated by ERK1/2 activation (35). Furthermore, furin can be phosphorylated in its 
cytoplasmic tail by casein kinase II which controls its trafficking to the TGN (20). In the 
current study, ERK1/2 inhibition results in an increase in the pro-form of MT1-MMP, 
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which could be explained by a defect in its processing to the active form of the enzyme. 
Our findings indicate that additional studies are needed to further investigate the role of 
ERK1/2 inhibition on the trafficking of furin to the TGN. Finally, when cells are 
stimulated by growth factors such as PDGF-BB, they can quickly mobilize intracellular 
stores of MT1-MMP to the cell surface, often to specialized membrane protusions 
known as lamellipodia or invadopodia where ECM degradation occurs (34). Previous 
studies have shown this process is regulated by both the PI3K/Akt and ERK1/2 
pathways, and our results from this study are consistent with those findings. 
Although we demonstrated the importance of PDGFR signaling during postnatal 
tendon growth and remodeling, there are several limitations to the current study. We 
used a specific inhibitor of PDGFRα and PDGFRβ, and while the off-target effects of 
this inhibitor were minimized due to its affinity for the PDGFRs compared to other 
structurally related kinases, we were not able to selectively inhibit each receptor to 
determine its individual function (38). It also remains possible that some of the observed 
changes in tendon growth were due to the effect of the PDGFR inhibitor on the plantaris 
muscle (46). However, even if PDGFR inhibition resulted in less force production by the 
overloaded plantaris muscle, we would still expect the plantaris tendon to be loaded 
during the muscle-independent phase of gait. Whereas more than 20 MMPs have been 
described, we only silenced MT1-MMP during our migration assays, thus it remains 
possible that other MMPs are also important for tendon fibroblast migration (32). 
Additionally, we measured differences in tendon morphology after mechanical overload 
due to PDGFR inhibition, but tendon mechanics and other functional assays were not 
performed. The synergist ablation procedure is reliable, reproducible and can be simply 
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executed, but the mechanical load placed on the plantaris tendon is greater than that 
experienced during normal locomotion. Furthermore, while our study focused only on 
the plantaris tendon, observed differences might not be reflected in other trunk or limb 
tendons. We measured the expression of many transcripts using microarray and qPCR, 
but changes in the transcriptome might not follow changes in the proteome. Finally, we 
collected data at only two time points after mechanical overload, and perhaps longer 
term experiments may provide additional mechanistic insight. 
In summary, this is the first study to demonstrate that a family of RTKs, namely 
PDGFRα and PDGFRβ, and their ligands, the PDGFs, are necessary for proper tendon 
growth and remodeling in the adult. As with all physiological processes, normal tendon 
function is the result of a complex interplay between the cells that make up the tissue 
and their local ECM environment. While we demonstrate that PDGFR signaling is a key 
regulator of tendon fibroblast proliferation and migration, it is interesting to note that 
dysfunctional PDGFR activity has been linked to a hypercellular phenotype that is 
commonly seen in painful tendinopathies (39), and that PDGFs are upregulated and 
active at multiple stages of the healing process in injured tendons (29, 55). Knowledge 
of PDGF-dependent processes has led to the development of newer technologies such 
as PDGF-BB-coated sutures, which are currently being tested for clinical use in 
lacerated flexor tendons (4). However, further studies are needed that selectively 
inactivate each PDGFR subtype in order to parse out their individual functions, and 
provide additional mechanistic insight into the role of PDGFR signaling in tendon tissue. 
Given the limited treatment options available for tendon injuries and diseases, a better 
understanding of PDGFR signaling and the fundamental cellular and molecular 
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mechanisms that it regulates during tendon growth will help inform regenerative 
strategies for these debilitating conditions. 
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Figure 3.1. Tendon fibroblasts express both PDGFRα and PDGFRβ. (A) Schematic of 
the synergist ablation procedure. All histological sections were taken from the 
midportion of the plantaris tendon. Representative images of (B) non-overloaded, (C) 3-
day overloaded and (D) 10-day overloaded plantaris tendons. Dashed white line 
indicates the boundary between the original tendon and neotendon. White arrowheads 
indicate blood vessels composed of PDGFRα-/PDGFRβ+ cells. Scale bars are 100 μm. 
(E) Tendon fibroblasts were isolated from PDGFRαeGFP/+ mice and immunostained for 
PDGFRβ. PDGFRα and PDGFRβ signals were observed in all cells. Scale bar is 50 
μm. DAPI, blue; PDGFRα-H2B-eGFP, green; PDGFRβ, red. 
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Figure 3.2. CP-673,451 inhibits phosphorylation of PDGFRα and PDGFRβ in tendon 
fibroblasts. (A) Representative immunoblots of serum-starved tendon fibroblasts treated 
with 20 ng/ml of PDGF-BB for 30 minutes with or without 1 μM of the PDGFR inhibitor 
CP-673,451. A Coomassie stained membrane is shown as a loading control. (B) 
Representative immunoblots of 3-day overloaded plantaris tendons demonstrating the 
ability of CP-673,451, to inhibit phosphorylation of PDGFRα and PDGFRβ in vivo. 
Phosphorylation of Akt and ERK1/2 were also inhibited by PDGFR inhibitor treatment. 
β-tubulin is shown as a loading control. (C) Immunohistochemistry of 3-day overloaded 
plantaris tendons treated with vehicle or PDGFR inhibitor demonstrates a decrease in 
the abundance of p-PDGFRα/PDGFRβ-expressing cells in the overloaded plantaris 
tendons treated with CP-673,451 relative to vehicle-treated controls. Scale bars are 10 
μm. DAPI, blue; WGA, green; p-PDGFRαY849/PDGFRβY857, red. 
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Figure 3.3. Inhibition of PDGFR signaling prevented growth of plantaris tendons 
subjected to mechanical overload. (A) Representative cross sections of 3- and 10-day 
overloaded plantaris tendons, treated with vehicle or PDGFR inhibitor, and stained with 
hematoxylin and eosin. Dashed black line indicates the boundary between the original 
tendon and neotendon. Scale bar is 250 μm. Quantitative analysis of (B-D) cross-
sectional area (CSA, in mm2) and (E-G) cell density (cells/mm2) for the original tendon, 
neotendon and total tendon. Values are mean±SD. N=5 tendons for each group. 
Differences between groups were tested using a two-way ANOVA (α=0.05) followed by 
Tukey‘s post hoc sorting: different (P<0.05) from a, 3D vehicle; b, 3D PDGFR inhibitor; 
c, 10D vehicle. 
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Figure 3.4. PDGF-BB stimulates proliferation of tendon fibroblasts in vitro. (A) In vitro 
proliferative activity of tendon fibroblasts was measured by BrdU uptake in the presence 
of 0.5% FBS with or without 20 ng/ml of PDGF-BB treatment. Proliferating cells were 
double labeled for DAPI (blue) and BrdU (red), and marked by white arrows. (B) 
Proliferative activity was quantified as mean±SD in 5 randomly selected fields of a 
single experiment from 6 independent experiments performed. Differences between 
groups were tested using an unpaired t-test; a, P<0.05. 
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Figure 3.5. Inhibition of PDGFR signaling decreases tendon fibroblast proliferation in 
vivo. (A) Representative Ki67 immunostaining of 3- and 10-day overloaded plantaris 
tendons, treated with vehicle or PDGFR inhibitor. Dashed white line indicates the 
boundary between the original tendon and neotendon. Scale bars are 100 μm. DAPI, 
blue; WGA, green; Ki67, red. (B-D) Quantitative analysis of proliferating cells (Ki67+ 
nuclei/mm2) for the original tendon, neotendon and total tendon. Values are mean±SD. 
N=4 tendons for each group. Differences between groups were tested using a two-way 
ANOVA (α=0.05) followed by Tukey‘s post hoc sorting: different (P<0.05) from a, 3D 
vehicle; b, 3D PDGFR inhibitor; c, 10D vehicle. 
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Figure 3.6. Microarray. (A) Heat map and (B) Venn diagram demonstrating the unique 
and overlapping transcripts that were greater than 1.5-fold upregulated or 
downregulated compared to non-overloaded plantaris tendons. The key to the left of the 
heat map assigns colors to absolute expression values of genes on a log2 scale. (C) 
Graphical representation of gene ontology enrichment analysis of overloaded plantaris 
tendons treated with PDGFR inhibitor relative to vehicle-treated controls. 
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Figure 3.7. Inhibition of PDGFR signaling prevents the expression of angiogenesis, 
ECM synthesis and remodeling, cell specification and proliferation, and cell migration 
genes in plantaris tendons subjected to mechanical overload. Quantitative expression of 
(A) angiogenesis, (B) ECM synthesis, (C) MMPs and TIMPs, (D) cell specification and 
proliferation, and (E) cell migration genes in 3- and 10-day overloaded plantaris 
tendons, treated with vehicle or PDGFR inhibitor. Target gene expression was 
normalized to the stable housekeeping gene peptidylprolyl isomerase D (PPID), and 
further normalized to plantaris tendons that were not subjected to synergist ablation. 
Values are mean±SD. N=5 tendons for each group. Differences between groups were 
tested using a two-way ANOVA (α=0.05) followed by Tukey‘s post hoc sorting: different 
(P<0.05) from a, 3D vehicle; b, 3D PDGFR inhibitor; c, 10D vehicle. 
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Figure 3.8. Effect of PDGF-BB treatment on collagen expression, and validation of 
MT1-MMP siRNA. Quantitative expression of (A) Col1a1 and (B) Col1a2 transcript 
levels in tendon fibroblasts treated with 20 ng/ml of PDGF-BB for 1, 2, 4, 8 and 12 hours 
in low-serum conditions. Values are mean±SD for 3 biological replicates. Differences 
between groups were tested using one-way ANOVA (P<0.05). No significant differences 
were found between groups. (C) Representative immunoblots of Pro-Col1a1 protein 
levels in tendon fibroblasts treated with 20 ng/ml of PDGF-BB for 24 hours in low-serum 
conditions. β-tubulin is shown as a loading control. (D) Representative phase contrast 
image of tendon fibroblasts transfected with fluorescent-labeled MT1-MMP siRNA (red) 
demonstrating >98% transfection efficiency. (E) Quantitative expression of MMP2, 
MMP9 and MT1-MMP mRNA in tendon fibroblasts transfected with scrambled or MT1-
MMP siRNA for 48 hours demonstrating specificity and efficiency of MT1-MMP mRNA 
knockdown. Differences between scrambled siRNA and MT1-MMP siRNA for each 
gene were tested using t-tests; a, P<0.05. 
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Figure 3.9. PDGF-BB stimulates tendon fibroblast migration in vitro. (A) Schematic 
representation of the in vitro migration assay. (B) Representative images of tendon 
fibroblasts obtained 6 days after being placed on the surface of a tendon ECM transwell 
system, treated with no additional growth factors (control), TGF-β1, PDGF-BB, and 
PDGF-BB + BB-94 (a synthetic broad spectrum MMP inhibitor). Quantification of (C) the 
number of migrating cells per field and (D) maximum distance migrated. Values are 
mean±SD. N=4 replicates per group. Differences between groups were tested using a 
one-way ANOVA (α=0.05) followed by Tukey‘s post hoc sorting: different (P<0.05) from 
a, control; b, TFG-β1; c, PDGF-BB. 
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Figure 3.10. MT1-MMP is required for PDGF-BB-mediated fibroblast migration through 
tendon ECM. (A) Representative images of tendon fibroblasts transfected with 
scrambled siRNA or MT1-MMP siRNA, and treated with PDGF-BB,  measured after 6 
days. Quantification of (B) the number of migrating cells per field and (C) maximum 
distance migrated of the MT1-MMP-silenced tendon fibroblasts. Values are mean±SD. 
N=4 replicates per group. Differences between groups were tested using an unpaired 
Student’s t-test; a, P<0.05. 
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Figure 3.11. PDGF-BB stimulation of tendon fibroblasts activates PI3K/Akt and ERK1/2 
pathways, which both in turn mediate tendon fibroblast migration through tendon ECM. 
(A) Representative immunoblots of total and phospho PDGFRα, PDGFRβ, ERK1/2, Akt 
and p70S6K from serum-starved tendon fibroblasts treated with PDGF-BB for 5, 15, 30 
and 60 minutes. β-tubulin is shown as a loading control. (B) Representative images of 
tendon fibroblasts obtained 6 days after being placed on the surface of a tendon ECM 
transwell system, treated with PDGF-BB, PDGF-BB + PD98059, or PDGF-BB + 
Wortmannin. Quantification of (C) the number of migrating cells per field and (D) 
maximum distance migrated. Values are mean±SD. N=4 replicates per group. 
Differences between groups were tested using a one-way ANOVA (α=0.05) followed by 
Tukey‘s post hoc sorting: different (P<0.05) from PDGF-BB; b, PDGF-BB + PD98059. 
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Figure 3.12. PDGF-BB does not regulate MT1-MMP mRNA abundance, but does 
increase MT1-MMP protein levels through a PI3/Akt-dependent mechanism. (A) 
Quantification of MT1-MMP transcript levels in tendon fibroblasts treated with 20 ng/ml 
of PDGF-BB for 1, 2, 4, 8 and 12 hours in low-serum conditions. Values are mean±SD 
for 3 replicates. Differences between groups were tested using one-way ANOVA 
(P<0.05). (B) Representative immunoblots of Pro-MT1-MMP (63 kD), active MT1-MMP 
(60 kD), processed MT1-MMP (45 kD), and phospho and total ERK1/2 and Akt are 
shown, from tendon fibroblasts incubated alone or with PDGF-BB in the presence or 
absence of PD98059 or Wortmannin for 24 hours. β-tubulin is shown as a loading 
control. Quantification of (C) p-ERK1/2T202/Y204, (D) p-AktT308, (E) total MT1-MMP, (F) pro-
MT1-MMP, (G) active MT1-MMP and (H) processed MT1-MMP protein levels. (I) Ratio 
of the pro- to active form of MT1-MMP. Values are mean±SD for 6 biological replicates. 
Differences between groups were tested using a one-way ANOVA (α=0.05) followed by 
Tukey‘s post hoc sorting: a, different (P<0.05) from control; b, PDGF-BB; c, PDGF-BB + 
PD98059. 
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Figure 3.13. PDGF-BB-dependent membrane trafficking of MT1-MMP in tendon 
fibroblasts is regulated by the PI3K/Akt and ERK1/2 pathways. (A) Representative 
immunoblots of cell surface MT1-MMP protein levels in tendon fibroblasts after 
incubation alone or with PDGF-BB in the presence or absence of PD98059 or 
Wortmannin for 24 hours in low-serum conditions. Coomassie staining is shown as a 
total protein loading control. (B) Representative immunoblots of the membrane fraction 
and whole cell lysates of tendon fibroblasts using MT1-MMP and GAPDH as typical 
membrane and cytosolic proteins, respectively. Due to the isolation process, membrane 
fraction lanes run in a more narrow fashion. (C) Quantification of cell surface MT1-MMP 
protein levels. Values are mean±SD for 3 biological replicates. Differences between 
groups were tested using a one-way ANOVA (α=0.05) followed by Tukey‘s post hoc 
sorting: a, different (P<0.05) from control; b, PDGF-BB; c, PDGF-BB + PD98059. (D) 
Diagram of PDGF-BB-dependent regulation of MT1-MMP expression and membrane 
trafficking in tendon fibroblasts.  
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Gene Description Forward Primer (5’-3’) Reverse Primer (3’-5’) Size (bp) 
Reference 
Sequence 
Amotl2 Angiomotin-like 2 AACCGCCACCTGGCAAGCAA GGTCCTCGATGGCACCACGC 148 NM_019764.2 
Ankrd1 Ankyrin repeat domain 1 
(cardiac muscle) 
AAACGGACGGCACTCCACCG 
 
CGCTGTGCTGAGAAGCTTGTCTCT 
 
210 NM_013468.3 
Anln Anillin, actin binding protein TGGGGCTGAGCAGATGGTCG TCCGGGACTGGCCATAACTGAAGA 274 NM_028390.3 
Cd146 
(Mcam) 
Melanoma cell adhesion 
molecule 
GTGAATCCAACTGCCCCTGA 
 
CCATGCAGAGATACCGTCCC 
 
184 NM_023061.2 
Cd248 CD248 antigen, endosialin CTGTGCGTGAAACAGCCTTC TCCACACACTCATGTTCGCA 110 NM_054042.2 
Col1a1 Collagen, type I, alpha 1 ACTGCAACATGGAGACAGGTCAGA ATCGGTCATGCTCTCTCCAAACCA 128 NM_007742.4  
Col1a2 Collagen, type I, alpha 2 CCAGCGAAGAACTCATACAGC GGACACCCCTTCTACGTTGT 105 NM_007743.2 
Col3a1 Collagen, type III, alpha 1 ACGTAAGCACTGGTGGACAG CAGGAGGGCCATAGCTGAAC 98 NM_009930.2 
Col4a1 Collagen, type IV, alpha 1 GGCAGGTCAAGTTCTAGCGT TGGCCTGATGTTGGTAACCC 106 NM_009931.2 
Col5a1 Collagen, type V, alpha 1 GGAGAGCCACGTGTTCTGTAG GAGGGAATGAGGCATGGCAG 135 NM_015734.2 
Col6a1 Collagen, type VI, alpha 1 AAAGGCACCTACACCGACTG GCATGGTTCCTTGTAGCCCT 135 NM_009933.4 
Ctgf Connective tissue growth 
factor 
CCCTGCCCTAGCTGCCTACCG 
 
GCTTCGCAGGGCCTGACCAT 
 
204 NM_010217.2 
Cyr61 Cysteine rich protein 61 GCCGTGGGCTGCATTCCTCT GCGGTTCGGTGCCAAAGACAGG 262 NM_010516.2 
Diaph3 Diaphanous related formin 
3 
GAGAAGCGACCCAAGTTGCAT GAAGGGGAGGTCTCTCTTTCTT 109 NM_019670.1 
Egr1 Early growth response 1 CAGCGCCTTCAATCCTCAAG GCGATGTCAGAAAAGGACTCTGT 78 NM_007913.5 
Egr2 Early growth response 2 GGTTGTGCGAGGAGCAAATG GGCAGCTGGTGCATAAAACC 82 NM_010118.3 
Flna Filamin, alpha GTACCGTGTCCGGGCTGTGC ACATGCTCGCCACCGAAGCG  276 NM_010227.3 
Mki67 Marker of proliferation Ki67 TCGTGTTACTGGCAGACGAC ACCGCAGCTTGGTTTCTAGT 111 NM_001081117.2 
Mkx Mohawk homeobox CAACCCGTACCCTACGAAGA AGCCGACGTCTAGCATTAGC 102 NM_177595.4 
Mmp2 Matrix metallopeptidase 2 GACCTTGACCAGAACACCATC CATCCACGGTTTCAGGGTCC 163 NM_008610.2 
Mmp8 Matrix metallopeptidase 8 TACAGGGAACCCAGCACCTA CCACGGAGTGTGGTAGTAGC 158 NM_008611.4 
Mmp9 Matrix metallopeptidase 9 AACACCACCGAGCTATCCAC AGGAGTCTGGGGTCTGGTTT 163 NM_013599.2 
Mmp13 Matrix metallopeptidase 13 CAGTTGACAGGCTCCGAGAA TTCACCCACATCAGGCACTC 119 NM_008607.2 
Mmp14 Matrix metallopeptidase 14 
(membrane-inserted) 
AGGCTGATTTGGCAACCATGA CCCACCTTAGGGGTGTAATTCTG 172 NM_008608.4 
Myl9 Myosin, light polypeptide 9, 
regulatory 
AGGCCTCAGGCTTCATCCACGA 
 
ATGGGGTCTAGGCACTGGGGC 
 
216 NM_172118.1 
Pecam
1 
Platelet/endothelial cell 
adhesion molecule 1 
GGAAGTGTCCTCCCTTGAGC 
 
CCTTCCGTTCTTAGGGTCG 
 
98 NM_008816.3 
Ppid Peptidylprolyl isomerase D 
(cyclophlin D) 
AGTGAAGATGTCCCACGCAT 
 
CCACGTCAAAGAAGACTCGC 
 
74 NM_026352.3 
Scx Scleraxis CCTTCTGCCTCAGCAACCAG GGTCCAAAGTGGGGCTCTCCGTGACT 156 NM_198885.3 
Tagln Transgelin AGGCGGCCTTTAAACCCCTCACC CGGCCTACATCAGGGCCACAC 244 NM_011526.5 
Tsp1 Thrombospondin 1 TCCAGCTCAGCTACCAAGGTC AGGAGAGGCCACAGATAGCTT 127 NM_011580.4 
Timp1 Tissue inhibitor of 
metalloproteinase 1 
CTTGGTTCCCTGGCGTACTC 
 
ACCTGATCCGTCCACAAACAG 
 
150 NM_011593.2 
 
Timp2 Tissue inhibitor of 
metalloproteinase 2 
TCAGAGCCAAAGCAGTGAGC 
 
GCCGTGTAGATAAACTCGATGTC 
 
142 NM_011594.3 
 
Tnmd Tenomodulin TGTACTGGATCAATCCCACTCT GCTCATTCTGGTCAATCCCCT 114 NM_022322.2 
Vegfa Vascular endothelial 
growth factor A 
CGTCCAACTTCTGGGCTCTT 
 
CAGCTCCGATCGGTTTGTCT 
 
74 NM_001025250.3  
 
Table 3.1. Primer sequences used for quantitative PCR. 
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Chapter IV 
 
Conclusions 
 
Tendon is one of the primary effectors of locomotion by enabling efficient force 
transmission from skeletal muscle to bone. As with all biological systems, proper tendon 
function is highly dependent on the macromolecular structural organization and 
biochemical composition of its extracellular matrix (ECM). Tendon is a dynamic tissue, 
and as such, it reacts to externally applied loads by adapting its ECM, as evidenced by 
increases in tendon cross-sectional area (CSA), cell density, peak stress, peak strain 
and type I collagen content (19, 33-35, 42, 43, 67). While many of these adaptations are 
due to the ability of tendon fibroblasts to sense and respond to biomechanical cues in 
their local ECM environment (66, 69), the tendon ECM also selectively binds and 
releases various growth factors that regulate multiple cellular functions through the 
activation of transmembrane receptors and their downstream signaling cascades (3, 
20). The objective of this dissertation was to determine the role of key signaling 
pathways activated during tendon growth and injury, and to investigate the biological 
mechanisms behind these responses. Since a central feature of tendon disorders is 
abnormal fibroblast morphology and a grossly disrupted appearance of the tendon 
ECM, my overall working hypothesis is molecular programs that regulate the interaction 
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between tendon fibroblasts and their local ECM environment during tendon growth play 
an important role in the healing response of injured tendons. Herein, we demonstrated 
that platelet-derived growth factor (PDGF) ligands and their receptors (PDGFRs) are 
necessary for postnatal tendon growth and remodeling in the adult. We utilized an 
integrative approach that coupled structural and functional studies of PDGFR-inhibited 
tendons with cell culture experiments that established the molecular mechanisms 
responsible for the observed differences in tendon growth. Taken together, this 
dissertation addresses fundamental gaps in the field of musculoskeletal biology by 
providing a focused examination of key molecular programs activated in response to 
tendon injury, namely epithelial-to-mesenchymal transition (EMT) and matrix 
metalloproteinase (MMP) genes (Chapter II). Using an informative overload model that 
recapitulates the critical elements of tendon growth, we found that PDGFR signaling 
regulates changes in tendon structural and functional properties in response to 
mechanical growth stimuli (Chapter III). The main conclusions of this dissertation are 
briefly summarized as follows: 
 
1. M2 macrophages are normally present within the interfascicular matrix or 
endotenon of uninjured tendons. Tendon transection followed by acute repair 
leads to an early and dramatic influx of M1 macrophages within the injured 
tendon tissue. M2 macrophages slowly accumulate in areas of newly formed 
tendon tissue and become the predominant macrophage phenotype by 28 
days (Chapter II). 
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2. Tendon transection followed by acute repair is accompanied by significant 
changes in the tendon transcriptome, including activation of genes in the EMT 
and MMP families (Chapter II). 
3. Tendon fibroblasts express both PDGFRα and PDGFRβ, and signaling 
through these receptors is required for postnatal tendon growth and 
remodeling in the adult, primarily due to defects in proliferation and migration 
of tendon fibroblasts (Chapter III). 
4. Membrane type-1 matrix metalloproteinase (MT1-MMP) is an essential 
proteinase for tendon fibroblast migration through cross-linked type I collagen 
hydrogels that closely recapitulate the tendon ECM environment in vivo 
(Chapter III). 
5. PDGF-BB-dependent MT1-MMP expression by tendon fibroblasts is 
regulated via PI3K/Akt-mediated translational and ERK1/2-mediated post-
translational mechanisms. Inhibition of PI3K/Akt and ERK1/2 pathways also 
prevents PDGF-BB-dependent membrane trafficking of active MT1-MMP to 
the cell surface in tendon fibroblasts (Chapter III). 
 
In recent years, the most significant advances in tendon research that have 
contributed to our current understanding of tendon biology have occurred in the field of 
tendon development (23, 26, 29, 45, 51, 52). The motivation for many of these 
developmental studies in tendon stems from the clinically relevant problem of 
tendinopathy. In this regard, findings from studies of tendon development have made a 
substantial impact on research efforts aimed at understanding the molecular biology of 
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tendon injury and repair, by facilitating the generation of ScxGFP reporter mice, as well 
as constitutive and inducible Cre lines driven by the Scx promoter, to be used as 
experimental tools (9, 51). Several transcription factors with functional roles in tendon 
differentiation, including Scx (45), mohawk (Mkx) (29), and early growth response 1 and 
2 (Egr1 and Egr2) (17, 38), are also known to be upregulated following tendon injury 
suggesting that these transcription factors may play dual roles in tendon development 
and regeneration (Chapter II) (13, 59). Additionally, the transcription factors Mkx and 
Egr1 have been used to promote tenogenesis of mesenchymal stem cells for 
implantation in critical tendon defects to encourage healing in various animal models 
(17, 41). Similar to developmental studies of tendon, fully elucidating the molecular 
mechanisms that govern tendon growth and remodeling may also inform regenerative 
strategies for the treatment of tendon injuries and diseases. 
 
Commentary and Future Directions 
  
The importance of macrophages to the healing of injured musculoskeletal tissues 
is well documented (64). In Chapter II, we demonstrated the precise location of M1 and 
M2 macrophages in uninjured tendon tissue, as well as the sequence and timing of their 
accumulation following a physiologically relevant tendon injury. Compared to skeletal 
muscle tissue, M1 macrophages persist longer and M2 macrophages appear later. This 
may partially explain the protracted course of tendon healing relative to skeletal muscle 
tissue. It may also offer an opportunity to accelerate tissue healing in tendons after an 
injury occurs, either by promoting earlier removal of the M1 macrophages or the earlier 
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arrival of M2 macrophages. However, a major limitation to macrophage research is the 
absence of transgenic animals models that can target specific macrophage 
subpopulations (47). At the moment, transient reductions in entire macrophage 
populations is possible via antibody-mediated depletion by targeting the colony 
stimulating factor 1 receptor (CSF1R) (11), diphtheria-toxin mediated killing (54) or 
administration of gadolinium chloride or clodronate liposomes (2, 15). However, 
alternative approaches would be to use a drug such as azithromycin or fasudil (40, 46) 
that induces an earlier switch in macrophage phenotype from M1 to M2, or cell-based 
therapies where M2 macrophages are isolated and injected into the site of repair. This 
technique has demonstrated mixed results in the past when used in diabetic cutaneous 
wounds or traumatic muscle injury (30, 48), but has not been tried in injured tendon 
tissue, and perhaps the results are tissue dependent. Taken together, more 
sophisticated transgenic animal models are greatly needed that can selectively delete 
M1 and M2 macrophages with spatiotemporal control, and therefore more accurately 
address the molecular mechanisms responsible for impaired tendon regeneration.  
Using a physiologically relevant tendon injury model (Chapter II), we identified 
that Snail1 and other similar genes that play important roles in EMT-dependent 
processes were coordinately regulated throughout the tendon repair process. These 
EMT-related genes not only play a central role in the EMT program, but are also 
involved in well established EMT-independent functions, including ECM remodeling, cell 
lineage specification and cell cycle regulation (6, 56, 65). While whole tendons can be 
dissociated to release putative tendon stem cells that have higher proliferative rates 
than tendon fibroblasts and possess the ability to differentiate into multiple other cell 
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types (8), the location and identity of these cells in vivo within intact tendons remains 
unknown. Several lines of evidence suggest that these cells might be concentrated in 
the epitenon (19, 43, 55, 60), which is a loose epithelial-like tissue layer that surrounds 
the tendon and is subtended by a basement membrane, a specialized form of ECM that 
is normally found beneath all epithelial cells. In other tissues, the epithelium can 
potentially serve as a source of fibroblasts during responses to tissue injury through a 
process known as EMT (31). However, in the case of tendon, whether the fibroblasts 
emerging from the epitenon in response to mechanical loading are of epithelial origin 
remains unknown. To address this question, a marker specific of the epitenon would 
need to be identified such that an inducible Cre driver could be made, and then crossed 
to a Rosa26-stopf/f-tdTomato mouse that is in the ScxGFP background (Figure 4.1). 
Using this approach, a lineage tracing experiment could be performed using a murine 
model of intrasynovial flexor tendon repair of the flexor digitorum longus (FDL) tendon 
(22). Not all tendons in the mouse have a well developed epitenon, especially the 
Achilles and plantaris tendons, but the tail tendons and flexor tendons of the fore and 
hind paws do have a basement membrane-like structure that stains positive for laminin 
and type IV collagen (unpublished data). Prior to acute transection and repair of the 
FDL tendon, we could induce permanent expression of tdTomato in all epithelial cells 
following tamoxifen treatment, and identify whether the fibroblasts that accumulate in 
the injured tendons are derived from epithelial cells. The presence of yellow cells (red 
and green overlap) would indicate fibroblasts that arose from epithelial progenitors, 
while fibroblasts that appeared green would indicate that EMT is not likely involved in 
tendon regeneration. 
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Other studies described in this dissertation (Chapter III) establish the importance 
of PDGFR signaling in tendon growth and remodeling in the adult. Our findings also 
provide compelling evidence for the role of at least one PDGF isoform in the 
proliferation and migration of tendon fibroblasts. However, a major obstacle 
encountered by studies of PDGF function is that signaling through PDGFRα and 
PDGFRβ in vitro demonstrates functional redundancy, while these receptors have 
distinct roles and expression patterns in vivo (68). One limitation of the studies 
described in this dissertation is that the use of a PDGFR inhibitor in vivo results in a 
global reduction of PDGFR signaling within tendon due to pharmacological blockade of 
both PDGFRα and PDGFRβ. Therefore, it is not possible to determine which PDGF 
isoforms and PDGFR subtypes are responsible for the proliferation and migration of 
tendon fibroblasts in the current studies. To determine the functional importance of the 
PDGFR subtypes in vivo, the following experiments are proposed. Since deletion of 
PDGFRα and PDGFRβ results in early embryonic lethality (25), spatiotemporal control 
of PDGFRα and PDGFRβ inactivation is required. To accomplish this, three mouse 
models (PDGFRαKD, PDGFRβKD and PDGFRαβKD) could be generated for the 
conditional knockdown of either PDGFRα, PDGFRβ or both PDGFRα and PDGFRβ 
specifically in tendon fibroblasts by crossing a ScxCreERT2/+ knock-in mouse with 
PDGFRαf/f, PDGFRβf/f and PDGFRαf/f:PDGFRβf/f, respectively (Figure 4.2). The 
ScxCreERT2/+ mice also have the ScxGFP transgene (51), which allows for the convenient 
identification of scleraxis (Scx)-expressing cells. In the PDGFRαKD, PDGFRβKD and 
PDGFRαβKD, CreERT2 is driven by the tendon-specific Scx promoter under the 
inducible control of tamoxifen. Mice would receive daily systemic injections of tamoxifen 
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for 3 days prior to overload and throughout the remainder of the study period. 
PDGFRαf/f, PDGFRβf/f and PDGFRαf/f:PDGFRβf/f mice do not have the CreERT2 allele, 
and thus will also receive tamoxifen treatment to serve as wild-type controls 
(PDGFRαWT, PDGFRβWT and PDGFRαβWT). Hindlimb synergist ablation will be 
performed as described in Chapter III and the mice will be allowed to recover for 3 or 10 
days, at which time the left plantaris tendons will be collected for gene expression 
analysis, and the right plantaris tendons will be used for histological examination or 
mechanical properties measurements. Efficiency of knockdown will be determined using 
qPCR with genomic DNA and primers that can quantify the floxed and null alleles. 
Collectively, the above experiments will help elucidate the specific functions of the 
PDGFR subtypes during postnatal tendon growth and remodeling in vivo. 
While inhibition of PDGFR signaling suppressed the normal growth of tendon 
tissue after mechanical overload (Chapter III), we had previously shown that PDGFR 
signaling is also required for skeletal muscle hypertrophy (58). This raises an important 
question of whether the consequences of PDGFR inhibition on tendon growth are direct 
or indirect, or in other words, is tendon growth possible in the absence of muscle 
hypertrophy? The primary function of tendon is to transmit load, and typically this load is 
generated proximally by muscular contraction. Muscle hypertrophy leads to increased 
force production, which increases the load transmitted by tendon, and this consequently 
results in tendon growth. However, tendons can also transmit loads that originate 
distally, such as those that arise during the heel strike phase of the gait cycle, and these 
loads are independent of muscular contraction. Thus, it remains possible that tendon 
growth can occur in the absence of muscle hypertrophy, although probably to a lesser 
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extent. To clarify this issue, experiments could be performed that genetically inactivate 
PDGFR signaling in a tissue specific manner using transgenic mouse models. 
Furthermore, analysis of the gene expression data sets from PDGFR-inhibited skeletal 
muscle and tendon tissue demonstrates overlapping changes in MMP expression, 
particularly with regard to MT1-MMP expression. This further highlights the significance 
of the complementary in vitro work in Chapter III identifying MT1-MMP as an essential 
proteinase for tendon fibroblast migration through tendon ECM, and provides additional 
support for the direct effect of PDGFR inhibition on tendon growth. 
Compared to other receptor tyrosine kinases (RTKs), there is less evidence to 
support the role of PDGFR signaling in many normal physiological functions such as 
tissue growth in the adult, despite its importance during embryonic development and in 
numerous pathological conditions (3). On the other hand, insulin-like growth factor 1 
(IGF-1) is another member of the RTK family that has been implicated in the growth of 
musculoskeletal tissues, and has been shown to be a positive regulator of skeletal 
muscle mass through its binding to the insulin-like growth factor 1 receptor (IGF1R) (1, 
18). Similar to the studies proposed for PDGFR signaling in this dissertation, it would be 
very interesting to determine the role of IGF1R signaling in postnatal tendon growth and 
remodeling. At the whole tissue level, IGF-1 appears to play an important role in type I 
collagen synthesis. Exercise and physical training can lead to increases in the local 
expression of IGF-1 in skeletal muscle and tendon tissue, accompanied by increases in 
type I collagen synthesis (24, 37, 44). Furthermore, local administration of IGF-1 in a 
collagenase model of flexor tendinitis in horses led to a reduction in core lesion size 
compared to saline injection, along with increases in tendon collagen content and 
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tendon stiffness (10). In a recent human study, injection of IGF-1 into the patellar tendon 
of healthy adults stimulated collagen synthesis both within the tendon as well as in the 
peritendinous tissue (21). In a rat overuse injury model, tendinopathic changes in the 
supraspinatus tendon were accompanied by reduced expression of type I and III 
collagen, IGF-1 and other genes associated with protein synthesis (5). 
While the signaling pathways activated by IGF-1 have not been described in 
detail in tendon, IGF-1 is known to have a potent effect on activating the 
phosphoinositide 3-kinase (PI3K) pathway with subsequent activation of p70 S6 kinase 
(p70S6K) via mechanistic target of rapamycin complex 1 (mTORC1), which increases 
ribosomal biogenesis and initiates mRNA translation (18). However, it remains to be 
determined whether the increases in type I collagen synthesis being measured at the 
whole tissue level following local IGF-1 administration are a direct effect of IGF-1 
binding to IGF1R, or are being mediated through another cell type, perhaps through the 
production of an intermediary factor or other signaling molecule. Additionally, IGF-1 has 
been shown to regulate the expression of other matrix proteins such as proteoglycans 
(PGs) and glycosoaminoglycans (GAGs) such as hyaluronic acid (28, 36, 61). 
Hyaluronic acid is responsible for forming an immature matrix during tendon growth that 
can serve as a scaffold for migrating cells and is later replaced by mature type I 
collagen (55). Thus, in addition to the regulation of type I collagen synthesis, another 
potential mechanism of IGF1R signaling during tendon growth is the imitation of matrix 
formation through hyaluronic acid production. 
To determine the role of IGF1R signaling during tendon growth and remodeling in 
the adult, the following experiments are proposed. First, cultured tendon fibroblasts 
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could be treated with a time course of IGF-1 to determine which major downstream 
signaling pathways are activated, and to determine if there is an IGF-1-dependent 
increase in type I collagen mRNA or protein levels, as well as the hyaluronic acid 
synthase enzymes. Small molecule inhibitors could then be used to block specific 
signaling pathways that were activated downstream of the IGF1R to measure their 
effect on matrix production. Next, to test the requirement of IGF1R signaling for tendon 
growth in vivo, ScxCreERT2 mice will be crossed to IGF1Rf/f mice and subjected to 
mechanical overload via the hindlimb synergist ablation model. Upon tamoxifen 
treatment, the IGF1R will be knocked down in Scx-expressing cells. If IGF1R signaling 
is regulating matrix production during tendon growth, we would expect a decrease in 
tendon CSA in the absence of IGF1R expression on tendon fibroblasts. Follow-up 
studies with proteomics, histology and electron microscopy will help provide an idea of 
the composition of the matrix in the mutant animals. Tendon mechanics can also be 
performed to test tendon function. These studies would provide mechanistic insights 
into the regulation of tendon ECM production with potential clues about the timing of 
therapy to encourage new matrix production in chronically degenerated tendons. 
Our findings in this dissertation earmark the growth factor PDGF-BB and 
proteinase MT1-MMP as potential targets for therapeutic intervention. Indeed, 
translational studies have already utilized the controlled delivery of PDGF-BB to 
enhance tendon healing in a canine model of intrasynovial flexor tendon repair with 
modest success (16, 62, 63). In Chapter III, our results demonstrate that PDGFR 
signaling primarily regulates proliferation and migration of tendon fibroblasts rather than 
ECM production, which may help better inform the timing of delivery of this growth factor 
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when used to augment tendon healing following injury. Recombinant human PDGF-BB 
has also been used to promote cutaneous wound healing in various diabetic animal 
models with mixed results (32, 39, 49, 50). However, PDGF-BB demonstrated 
encouraging results in a collagenase model of Achilles tendinopathy in a rat by 
improving mechanical properties compared to other commonly used treatments, 
including platelet-rich plasma (PRP) and steroids (57). Given that our findings 
demonstrate that PDGF-BB treatment of cultured tendon fibroblasts increases their 
proliferation and migration, logically it follows that intratendinous injections of 
recombinant human PDGF-BB into regions of hypocellularity and degenerated ECM in 
tendinopathic tendons may lead to the recruitment of local tendon fibroblasts and 
eventual tissue healing. Compared to PRP injections that contain variable amounts of 
PDGF-BB as well as numerous other growth factors (27), a potential advantage of 
purified recombinant human PDGF-BB is reproducible results due to precise dosing that 
also avoids the confounding effects of other growth factors present in PRP formulations. 
Finally, targeting MT1-MMP may also hold promise in the treatment of painful 
tendinopathies, since dysregulation of MMP activity is thought to be one of the 
underlying causes (12). In addition to degradation of multiple ECM components, other 
functions of MT1-MMP include activation of other secreted MMPs such as MMP2 (7), 
cleavage of matrix proteins that can create protein fragments then serve as signaling 
molecules or exposing cryptic epitopes that control angiogenesis in the tendon ECM 
that can lead to the infiltration of inflammatory cells (12, 53). There is also evidence to 
suggest that MT1-MMP can lead to the upregulation of COX-2, which is a potent 
mediator of pain and inflammation(4, 12) Low-level dosing of doxycycline, a potent 
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MMP inhibitor that also has antimicrobial properties, may block the activation of MMPs 
by MT1-MMP, although further clinical studies are needed before any definitive 
conclusions can be made (14). Taken together, our results from Chapters II and III 
suggest that MMP inhibition needs to be approached with caution because while 
inhibition may be helpful in pain and inflammation, it may also attenuate endogenous 
growth factor stimulated tendon fibroblast recruitment, which may in turn impair healing 
of the injured tendon. 
In summary, studies in this dissertation contribute to a growing body of work in 
the field of musculoskeletal regenerative medicine, and as our understanding of the 
cellular and molecular mechanisms of tendon biology advances, we will continue to 
improve therapies for the management of tendon injuries and diseases. 
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Figure 4.1. Targeting scheme for lineage tracing experiments. 
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Figure 4.2. Targeting scheme for genetic inactivation of PDGFRα and PDGFRβ. 
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